ࡱ>  q` RDbjbjqPqP::&$$$$%%%%8ܠ<% W"***ɹ_LUUUUUUU$[h^Ui%"ɹU$$**}ZVP\\\b$*%*U\U\\DN%6%* #AJ#*TV` WMJ^L ^L^%8?*i\ ???UU^??? W%%' %%' %%%$$$$$$ Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\NeNS6RoN gPlQSShandong Xinhua Pharmaceutical Company Limiteda joint stock company established in the People s Republic of China with limited liability Stock Code: 0719 2010 ANNUAL RESULTS ANNOUNCEMENTThe board of directors (the  Board ) and directors (Directors) of Shandong Xinhua Pharmaceutical Company Limited (the Company) hereby announces the audited consolidated results of the Company and its subsidiaries (the Group) for the year ended 31 December 2010. The following financial information has been prepared in accordance with Hong Kong Generally Accepted Accounting Principles (HKGAAP) and the Peoples Republic of China (PRC) accounting standards. This results announcement (the Announcement) is summarised from the annual report (the Annual Report) and investors are advised to read the full text of the Annual Report to understand the full details. The Announcement is published in Chinese and English. If there are any discrepancies between the Chinese version and the English version, the Chinese version shall prevail. I. Financial summary(i) Prepared in accordance with HKGAAP (Audited)Consolidated Income StatementItem2010 RMB0002009 RMB000 2008RMB000Revenue2,589,447 2,295,101 2,077,753 Profit before tax128,967 116,388 41,447 Income tax expense (22,159)(13,008)(5,677)Profit for the year106,808 103,380 35,770 Non-controlling interests5,509 3,6935,706 Profit attributable to owners of the Company101,299 99,687 30,064 Consolidated Statement of Financial PositionItem2010RMB0002009 RMB0002008 RMB000Total assets2,772,599 2,636,3632,159,424 Total liabilities(1,048,367)(955,542)(659,144)Non-controlling interests(38,010)(36,318)(33,746)Equity attributable to owners of the Company1,686,222 1,644,503 1,466,534 Prepared in accordance with PRC accounting standards (Audited) Financial dateItem2010 RMB 2009RMBChange as compared to the last year (%)2008RMBTotal operating income2,614,233,634.622,321,927,213.2512.592,096,963,709.91Profit before taxation125,128,440.97119,373,878.214.8246,040,186.22Profit attributable to the equity holders of the Company97,256,602.75102,244,346.19(4.88)33,965,477.41Profit attributable to the equity holders of the Company after extraordinary loss102,314,847.16109,058,885.67(6.18)43,449,423.86Net cash flow from operating activities173,000,248.75344,795,891.77(49.83)103,479,359.78ItemAs at 31 December 2010RMBAs at 31 December 2009RMBChange as compared to the end of last year (%)As at 31 December 2008RMBTotal assets 2,739,564,533.492,626,187,060.384.322,161,734,318.69Total equity attributable to equity holders of the Company1,676,523,546.191,633,645,846.352.621,453,252,991.36Capital (share)457,312,830.00457,312,830.00-457,312,830.00Financial summaryItem2010RMB2009RMBChange as compared to the last year (%)2008RMBBasic earnings per share0.210.22(4.55)0.07Diluted earnings per share0.210.22(4.55)0.07Basic earnings per share after extraordinary loss0.220.24(8.33)0.10Return on equity of weighted average% 5.816.83Decrease 1.02 points2.03Return on equity of weighted average after extraordinary loss% 6.117.28Decrease 1.17 points2.59Net cash flow from operating activities per share0.380.75(49.33)0.23ItemAs at 31 December 2010RMBAs at 31 December2009RMBChange as compared to the end of last year (%)As at 31 December 2008RMBNet assets per share attributable to equity holders of the Company3.673.572.803.18(iii) Reconciliation of accounts prepared in accordance with PRC accounting standards and HKGAAPProfit attributable to owners of the CompanyRMBNet assetsRMB20102009As at 31 December 2010As at 1 January 2010Prepared under HKGAAP101,299,000.0099,687,000.001,686,222,000.001,644,503,000.00Prepared under PRC accounting standards97,256,602.75102,244,346.191,676,523,546.191,633,645,846.35HKGAAP adjustments:Deferred taxation204,397.25427,653.81(1,711,546.19)(1,914,846.35)Depreciation charge due to revaluation in previous years - (1,432,000.00)(21,300,000.00)(21,300,000.00)Provision for education fund(1,362,000.00)(1,421,000.00)11,410,000.00 12,772,000.00 Surplus from revaluation for listing of H Shares - - 21,300,000.00 21,300,000.00 Others5,200,000.00(132,000.00) - - HKGAAP adjustments total4,042,397.25(2,557,346.19)9,698,453.8110,857,153.65  II. DIVIDENDSThe Board has announced and proposed a final dividend for the year ended 31 December 2010 of RMB0.05 per share in the Company (the Share) (approximately HK$0.059 per Share, including income tax) on 307,312,830 A Shares and 150,000,000 H Shares in issue. The proposed dividend is subject to approval by the shareholders of the Company at the Companys annual general meeting for the year 2010. An announcement in relation to the book closure period of the proposed dividend will be made in due course.III. MAIN BUSINESS AND FINANCIAL SITUATIONThe Group is mainly engaged in the development, production and sale of bulk pharmaceuticals, preparations, chemical products and other products. The profit of the Group is mainly attributable to its principal operations.Analysis of financial situation and operating results in accordance with PRC accounting standardsTotal assets of the Group as at 31 December 2010 was approximately RMB2,739,565,000, increased by approximately RMB113,378,000 or 4.32%, as compared with the figure of approximately RMB2,626,187,000 at the beginning of the year. The increase in total assets was mainly due to the increase of operation profits.Cash of the Group as at 31 December 2010 was approximately RMB404,050,000, slightly increased by approximately RMB2,156,000, as compared with the figure of approximately RMB401,894,000 at the beginning of the year. Total equity attributable to the shareholders of the Company as at 31 December 2010 was approximately RMB1,676,524,000, increased by approximately RMB42,878,000 or 2.62%, as compared with the figure of approximately RMB1,633,646,000 at the beginning of the year. This increase was mainly attributable to the increase of operation profits this year.The total liabilities of the Group as at 31 December 2010 were approximately RMB1,025,031,000, representing an increase of approximately RMB68,807,000 or 7.20%, as compared with the figure of approximately RMB956,224,000 at the beginning of the year. The increase was mainly attributable to part of the loans obtained by the Group from the bank to ensure the supply of funds, leading to an increase in the loans.Operating profit of the Group for the year of 2010 and net profit attributable to the Companys shareholders for 2010 amounted to approximately RMB131,702,000 and approximately RMB97,257,000 respectively, representing a slight decrease compared with those of the previous year. The decrease was mainly attributable to the increase in provision for impairment loss of assets and provision for wages and deferred income tax arising from the unrealized profit this year.The Groups net increase in cash and cash equivalents for the year of 2010 was approximately RMB3,672,000, representing a slight increase compared with the figure at the end of last year. Analysis under HKGAAPAs at 31 December 2010, the current ratio and the quick ratio of the Group was 167.77% and 111.55% respectively, and the rate of accounts receivable turnover (rate of accounts receivable turnover = revenue/average trade and bill receivables100%) and the rate of stock turnover (rate of stock turnover = cost of sales/average inventories100%) were 894.87% and 565.46% respectively.The Groups demand for working capital did not show significant seasonal fluctuation through the year.The Groups main source of funds was loans from financial institutions. As at 31 December 2010, the total amount of outstanding bank loans was approximately RMB475,528,000. As at 31 December 2010, cash on hand and in bank of the Group amounted to approximately RMB404,050,000 (including bank acceptance drafts deposits of approximately RMB35,980,000). The Group has stringent internal control systems for cash and fund management to strengthen its financial management. The Group maintained a good level of liquidity and had strong debt repayment ability.The Company invested RMB20,000,000 in cash to establish Xinhua (Zibo) Real Estate Company Limited in 2010. The company is mainly engaged in the business of real estate development and sale, the companys development prospect is good. Apart from the above transactions, the Group did not have any significant investment, acquisitions or asset disposals during this reporting period.As at 31 December 2010, the number of staff employed by the Group was 5,903, and the total amount for salaries and wages for 2010 was approximately RMB175,169,000.As at 31 December 2010, there was no charge on the Groups assets. The debt-to-capital ratio of the Group was 28.20% (debt-to-capital ratio = total borrowings / equity attributable to owners of the Company 100%).The bank balance of the Company will mainly be used as working capital for production and research and development.The assets and liabilities of the Group were mainly recorded in Renminbi. For the year ended 31 December 2010, the revenue from the Groups exports was approximately US$138,952,000, which may suffer from the risks associated with the fluctuation of exchange rates. Therefore, the Group has taken the following measures to lower the risks from the fluctuation of exchange rates: (1) the Group has increased the price of its export products to decrease the risks from the fluctuation of exchange rates; (2) the Group has made arrangements with overseas customers when entering into significant export contracts that the risks associated with the fluctuation in exchange rates shall be borne by both parties if the fluctuation exceeds the range of exchange rate fluctuation agreed by both parties.IV. business reviewIn 2010, the Group adhered to its development principles of changing the mode, adjusting the structure, grasping reforms and accelerating growth to actively counteract changes and adverse factors in the external operating environment, such as high raw material prices, pressure on environmental protection, appreciation of the Renminbi, national reform on the tender system for pharmaceutical products, and the downward price adjustment for drugs. The Group devoted itself to market expansion, park and project building, corporate management and scientific innovation, thereby enhancing its quality of financial performance. Looking back at 2010, the Group had the following achievements:1. Stepped up with market expansion to strengthen the quality of its financial performanceIn 2010, the Group maintained a double-digit growth for its operating revenue and reinforced its competitive edge in pharmaceutical products, greatly enlarging the market share and awareness in both domestic and overseas markets. Xinhua Pharmaceutical (Europe) GmbH (Xinhua Europe) played geographical advantages in Europe, achieving satisfactory revenue, with the annual sales revenue increasing by 50% from the year before.The Groups turnover from preparation products has increased 8%, compared with last year, enlarging the share of preparation sales in the industrial product sales by a considerable amount.The precision chemical engineering and pharmaceutical intermediates segments recorded rapid growth. Their share of the total operating revenue hiked from 0.56% in the previous year to 3.25%. The sales policy of leveling production, sales and return was emphasised to achieve an annual sales pay-back rate of 100%. As a result of increased effort in settling payments for goods, a total sum of RMB3,650,000 was settled in the year. The corporate financial performance has been greatly enhanced.2. Optimised production restructuring by using the facilities in the industrial parks and carrying out projects In 2010, the Group proceeded with the relocation of its headquarters plant with prudence. The procedures in relation to the land and relevant preferential policies for the Hutian District had been confirmed. Detailed design and plan verification for the chemical drug industrialisation centre and all functional areas had been completed. At the Shouguang Park, production of diketene and five other auxiliary pharmaceutical intermediates commenced one after another after successful production of the murexide line of products had begun. Several other next-stage projects were in their design or construction preparatory phase. To date, the production base for the Companys precision chemical engineering and pharmaceutical intermediates facility has been developed to a certain extent. The Modern Pharmaceutical Industry Innovation Park will soon commence operation.Smooth completion the above projects and the commencement of operations will consolidate the Companys innovative capacity and strengthen its integrated competitiveness.3. Reinforced efforts in scientific innovation and gained results in the development of new pharmaceutical productsIn 2010, the Company acquired approvals for the production of phenobarbital and clinical testing of calcium polycarbophils and tablets. Standard tribendimidine became a recognised item. Pazufloxacin mesilate and its sodium chloride injection passed technical assessment. Two products were undergoing application for clinical research, while three products had completed pilot production.During the year, the Company was recognised by the Shandong Provincial Department of Science and Technology and the Provincial State-owned Assets Supervision and Administration Commission, etc., as one of the second batch of pilot enterprises in the innovative sector. The brufen technological reformation and tribendimidine international collaboration projects were included in the third batch of the 11th Five-Year Plan under the Ministry of Science and Technologys key new drug innovation plans. The aspirin and paracetamol technological reformation projects were selected as the first batch of the 12th Five-year plan under the Ministry of Science and Technologys key new drug innovation plans.4. Enhanced internal management and improved corporate managementDuring the year, nine pharmaceutical products, one solid dosage line and a health food obtained the national GMP authentication. brufen, caffeine and dimethylxanthine received the Swiss GMP certification. Three products, brufen, trimethoprim and L-dopa, passed the FDAs on-site audit with zero defects. Currently the Company has seven products that have gone through FDA examination and ten that have passed the EDQM audit. Caffeine has passed the HACCP food quality system certification.During the year, 23 one strategy for one product quality technology projects were completed to enhance product quality. A total of RMB13,006,000 worth of raw materials were saved.New labour organisation was explored to raise employees productivity. The incentive scheme for R&D staff was strengthened to build a positive atmosphere for technological innovation.The Company was given the Outstanding Contribution Award by the China Equipment Management Annual Meeting, and recognised as Shandong Provinces Energy Calculation and Measurement Benchmark Enterprise and 2010 Chinas Top Pharmaceutical Company in relation to Corporate Social Responsibility.5. Expanded capital input, solved environmental problem, and achieved energy conservation and emission reductionCapital investment in energy conservation and emission reduction had been increased to promote relevant new energy-saving technologies. In 2010, the Company invested RMB8,900,000 and completed thirty-six energy-saving projects. On the foundation of a minimum 10% energy reduction for tens of thousands times of production capacity for three consecutive years, in 2010 the Company again obtained excellent result in this area, reducing energy consumption by 7.85% compared with 2009. In 2010, the Company invested RMB6,980,000 and achieved thirty-eight environmental measure projects, promoted the control of point sources, COD dropped by 6.08% as compared to last year. The Company was selected as a model enterprise in relation to recycling in Zibo City and Shandong Province. V. ProspectsIn 2011, as global demand gradually picks up and China adopts strategies to boost domestic demand, in particular the consumer demand. Therefore, it is expected that the demand for pharmaceutical products will increase. As it has been announced that bio-pharmacy as a national strategic emerging industry, pharmaceutical companies can count on more national policy support. After a few years of adjustments, the Group has entered a new phase for development, thus ensuring favourable conditions for its growth in 2011 and beyond.Meanwhile, the Company also has to tackle various undesirable factors: the aftershock of the global financial crisis has not completely dispersed; the Renminbi still comes under immense pressure to appreciate; the global currency dispute, scramble for resources and trade war are only in their prelude; the international oil price remains high; and the tightening of domestic credit makes financing more difficult. The supply surplus of pharmaceutical products is still pronounced; the launch of provincial tendering and procurement models for drugs increase the downward price pressure on pharmaceutical products. Manufacturing cost will surge under the pressure from eco-friendly measures, roll-out of new GMP and the increase in raw material prices, energy costs, transportation costs and salaries.In this connection, the main tasks of the Group in 2011 are as follows:1. Speed up the pace of restructuring to consolidate and raise the Companys status in the pharmaceutical marketThe Company will actively explore and increase the production of major bulk pharmaceuticals, focus on serial development of strategic products, raise the contribution ratio of new products, concentrate on research and development of specialty products and products with exceptional specifications, in order to further consolidate the dominance of the Companys chemical pharmaceutical products in the market. The Company will place emphasis on preparation. The Company will implement a strategy of product focus, strengthen marketing planning, and expand its key products. The Company aims to develop strategically important products with high gross margin and huge market potential, speed up the development of self-manufactured pharmaceutical preparations, and strengthen research and development of high value-added special products in order to raise profitability. The Company will, leverage on Shouguang Park as a base of operations, develop precision chemical engineering and pharmaceutical intermediates, so as to further strengthen the industry chain. The Company will fully implement new ideas on the development of pharmaceutical business, and with several years of effort, the scale of the Groups pharmaceutical business will expand and become the largest one in central Shandong. 2. Define strategic positioning to actively promote innovation of marketing modelsThe Company will actively focus on the sales of pharmaceutical products, implement marketing strategies, and on the basis of exploring innovative marketing models, strengthen marketing efforts on strategic products and high potential products, and strive to establish new points for economic growth. The Company will place great emphasis on two strategic positioning of the Company as Asias largest production and export base of anti-inflammatory drugs and the base for cardiovascular drugs, actively promote the implementation of extensive preparations strategy by insisting on marketing as the central theme, establishing high-end products brands, making profit from the sales of key products, expanding the production scale of popular products and further improving marketing process, refining target market and improving the marketing management system. The Company will strive to establish a new sourcing model and an information management system featuring day/week/month schedules, strengthen supplier management, implementation of online bidding for cost minimisation and the comprehensive safeguard of production. 3. Carry out projects and constructions in a scientific manner so as to lay down the foundation for the 12th Five-year Plan Shouguang Park project will enter a new phase of construction this year. In the construction process, the Company will mainly ensure quality control of the process, secure fund raising and guarantees, pay due attention to budgeting management and control, focus on project inspection and preparation for starting operations, strive to lower costs of project construction and pilot production, and make sure that the targets for production and efficiency are met within the shortest period of time. As this is the first year of full construction of Hutian District, the Company will carry out important works such as overall product coordination and planning, scientific layout for the park, procedure formulation and process optimisation, and will carry out the work in relation to design, construction, pilot production and product certification in a scientific manner so that Hutian District will be built to a high standard. During this year, the Modern Pharmaceutical Industry Innovation Park will open. The Group will leverage on such preferential policies for model enterprise of industrialisation and scientific innovation, to make the Park to become a world-class innovation base for modern science and technology in relation to management, research and development, evolution and achievements, which will significantly improve the Companys self-innovation capacity. 4. Insist on science and technological innovation to raise the Companys competitivenessFollowing the principle of market orientation, and by striking a balance among long-term, mid-term and short-term targets, the Company will continue its efforts in combined production, learning and research, raise R&D efficiency in various ways such as through its own or joint research and development, and speeding up the launch of new products. The Company will formulate the positioning for strategic products and key preparations as soon as practicable, and will establish a new product research and development system with focuses and appropriate reserve levels, which will be in line with the Companys strategies and planning. Basing on the policy one strategy for one product, the Company will conduct a full review on the existing new products so as to ensure a better selection and elimination of products. 5. Significantly promote the implementation of internationalisation strategy By making the best of product differentiation, optimisation and seriation, the Company will consolidate and raise the level of its international business in pharmaceuticals.The Company will carry out its three-step internationalisation strategy in relation to international trade, cooperation on preparations and overseas research, development and production in order to deepen international cooperation on preparations. Leveraging on the operation experiences from Xinhua Europe, the Company will target the European and the United States markets, reinforce efforts on research and development, speed up the implementation of the go global internationalization policy. On this basis, the Company will gradually establish overseas R&D and production bases which will lay down a solid foundation for internationalization of the Companys business. 6. Promote management innovation to raise management standards The Company will innovate the management system. Based on principles of simplicity, efficiency, advancement and science, the Company will streamline its structure, optimise its procedures and raise the segment and management efficiency. The Company will greatly promote such management innovations as technological quality, energy conservation and emission reduction, safety and eco-friendliness and risk control. The Company will strengthen the concept of market demand commands, whereby customer satisfaction and the accommodation of market demand are targets of management innovation. VI. Important IssuesStaff and RemunerationThe Groups staff remuneration was determined in accordance with State policies, the Companys profit in the corresponding period and the average income of local residents.As at 31 December 2010, the number of staff employed by the Group was 5,903, and the total amount of their salaries and wages for the year 2010 was approximately RMB175,169,000.Purchase, Sale or Redemption of the Companys Listed SecuritiesDuring the year ended 31 December 2010, the Company did not redeem the Companys listed securities. Neither the Company nor its subsidiaries, purchased, sold or redeemed any of the Companys listed securities.Connected TransactionsSignificant connected transactions carried out in the normal course of the Groups business are summarised as follows:Item2010 RMB0002009 RMB000With immediate holding companyShandong Xinhua Pharmaceutical Group Company Limited and its subsidiariesSale of water, electricity, steam and waste materials10,82410,258 Purchase of raw materials 64,40884,802Payment of annual trademark licence fee1,1001,100 Rental income-134 Design fees income550 Impairment losses on amounts due from fellow subsidiaries12,474- Rental expenses500500Consideration for acquisition of additional interests in subsidiaries-636With associates Sale of water, electricity, steam656- Purchase of raw materials 296,127 Design fees income-11With minority shareholders Sale of bulk pharmaceuticals and chemical raw materials130,031144,926 Purchase of chemical raw materials838514 In the opinion of the Directors (including the Independent Non-Executive Directors), the above transactions were carried out in the ordinary and usual course of the Groups business and on normal commercial terms. The aggregate amount of the above transactions for each of the years 2009 and 2010 did not exceed the annual cap approved in the general meeting of the Company.AuditorsThe accounts of the Company and the Group for this year prepared in accordance with HKGAAP and PRC accounting standards have been audited by SHINEWING (HK) CPA Limited and ShineWing, Certified Public Accountant, PRC respectively.The Company intends to re-appoint SHINEWING (HK) CPA Limited and ShineWing as international auditors and PRC auditors of the Company respectively for the year 2011 at the annual general meeting for the year 2010 to be held in 2011.Code on Corporate Governance PracticesThe Directors (including the independent non-executive Directors) are of the opinion that for the year ended 31 December 2010, the Company has complied with all requirements set out in the Code on Corporate Governance Practices including provisions contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.The Company has always strived to comply with the best practices of the Code on Corporate Governance Practices. Material Litigation and ArbitrationThe Group was not involved in any material litigation or arbitration and no material litigation or arbitration is pending or threatened or was made against the Group during the reporting period.Sale of AssetsDuring the reporting period, there were no material acquisitions and sales of assets, nor any material mergers.Amendments to the ArticlesDuring the reporting period, there were no amendments to the articles of association of the Company.Audit CommitteeThe audit committee has, together with the management, reviewed the accounting principles, practices and methods adopted by the Group and has reviewed the auditing, internal control and financial reporting of the Group. The audit committee has convened four meetings to review the audited financial statements for 2009, the unaudited 1st quarterly financial statements for 2010, the unaudited interim statements for 2010 and the unaudited 3rd quarterly financial statements for 2010.The audit committee convened a meeting on 17 March 2011 to review the 2010 audited accounts and annual results announcement.VII. FINANCIAL REPORTSThe financial reports of the Company and the Group for the financial year ended 31 December 2010 have been audited by SHINEWING (HK) CPA Limited (certified public accountants in Hong Kong) and ShineWing (certified public accountants in the PRC) in accordance with HKGAAP and PRC accounting standards respectively. In their respective auditors reports there was no qualified opinion.1. financial statement and notes Prepared Under PRC Accounting StandardsConsolidated and the Companys Income Statement for the year 2010 (AUDITED) Unit: RMBItem20102009Consolidated The CompanyConsolidatedThe Company1.Total operating income2,614,233,634.62 1,666,209,845.12 2,321,927,213.25 1,559,301,197.63  Includes: Operating income2,614,233,634.62 1,666,209,845.12 2,321,927,213.25 1,559,301,197.63 2.Total operating costs2,490,856,909.69 1,591,954,358.06 2,201,519,540.59 1,450,095,517.18  Includes: Operating cost2,133,691,060.29 1,370,885,913.46 1,877,427,603.27 1,239,789,642.29  Taxes and surcharges14,693,182.50 12,042,077.26 13,546,175.14 11,427,740.21  Selling expenses129,471,309.20 26,392,447.32 122,921,177.72 39,435,284.46  Administrative expenses165,142,770.60 134,908,546.18 159,579,455.09 133,230,876.27  Financial expenses21,701,647.06 23,458,453.18 26,777,339.32 26,300,296.79  Assets Impairment loss26,156,940.04 24,266,920.66 1,267,790.05 (88,322.84) Add: Gain or loss from changes in fair value--7,591,083.73 7,379,442.43  Investment gain or loss8,325,225.36 11,858,268.38 7,910,733.39 9,911,920.58  Includes: Investment gain or loss from related ventures and joint ventures5,259,770.20 5,259,770.20 4,911,640.58 4,911,640.58 3. Operating profit131,701,950.29 86,113,755.44 135,909,489.78 126,497,043.46  Add: Non-operating income10,041,631.62 5,190,633.15 6,808,717.69 6,178,390.64  Less: Non-operating cost16,615,140.94 15,306,112.32 23,344,329.26 22,323,342.80  Includes: Loss from the disposal of non-current assets13,424,913.38 13,404,692.70 19,605,908.29 19,413,164.47 4. Profit before taxation125,128,440.97 75,998,276.27 119,373,878.21 110,352,091.30  Less: Income tax expense22,362,744.90 10,513,609.30 13,436,120.20 11,459,004.77 5. Profit after taxation102,765,696.07 65,484,666.97 105,937,758.01 98,893,086.53  Includes: Profit attributable to the equity holders of the Company97,256,602.75 - 102,244,346.19  -  Minority interest5,509,093.32 -3,693,411.82  - 6. Earnings per share00 1) Basic earnings per share0.210.140.22 0.22  2) Diluted earnings per share0.210.140.22 0.22 7.Other comprehensive income(37,036,620.68) (36,112,737.05) 91,210,640.55 91,033,629.80 8. Total comprehensive income65,729,075.39 29,371,929.92 197,148,398.56 189,926,716.33  Includes: Total comprehensive income attributable to the equity holders of the Company60,543,341.34 - 193,403,969.35  -  Total comprehensive income attributable to minority interest5,185,734.05 - 3,744,429.21  -  Financial Notes:xe "s, 1. compared with the latest annual reportA th"1. During this reporting period, there was no change in accounting policies, accounting estimates or corrections of accounting errors of the Company.xe "nfluences, 2. in the range of consolidation as co"2. During this reporting period, Xinhua (Zibo) Real Estate Company Limited was added into the scope of consolidated financial statements of the Company. The company was established in December 2010 and the companys equity interest is RMB20,000,000.2. financial statements AND NOTES PREPARED UNDER HKGAAPCONSOLIDATED INCOME STATEMENTNOTESYear endedYear ended31/12/201031/12/2009RMB000RMB000Revenue32,589,4472,295,101Cost of sales(2,108,507)(1,849,738)Gross profit480,940445,363Investment income5,6254,928Other income21,0197,437Other gains and losses(20,642)(16,700)Distribution and selling expenses(145,900)(133,713)Administrative expenses(183,689)(162,845)Finance costs4(17,892)(19,378)Other expenses(15,754)(13,616)Share of profits of associates5,2604,912Profit before tax128,967116,388Income tax expense5(22,159)(13,008)Profit for the year6106,808103,380Profit for the year attributable to :Owners of the Company101,29999,687Non-controlling interests5,5093,693106,808103,380Earnings per share basic and diluted8RMB0.222RMB0.218CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Year endedYear ended31/12/201031/12/2009RMB000RMB000Profit for the year106,808103,380Other comprehensive (expense) income: Exchange differences arising on translation of foreign operation(924)(46) Fair value (loss) gain arising on available-for-sale investments (42,432)107,398Reclassification adjustments for the cumulative gains included in profit or loss upon disposal of available-for-sale investments(54)-Income tax relating to components of other comprehensive income6,373(16,140)Other comprehensive (expense) income for the year, net of tax(37,037)91,212Total comprehensive income for the year69,771194,592Total comprehensive income attributable to:Owners of the Company64,585190,848Non-controlling interests5,1863,74469,771194,592CONSOLIDATED STATEMENT OF FINANCIAL POSITIONNOTES31/12/201031/12/2009RMB000RMB000Non-current assetsTechnical know-how-117Property, plant and equipment1,007,323963,747Construction in progress120,261134,356Prepaid lease payments on land use rights222,703193,915Investment properties35,70736,694Interests in associates16,62014,360Available-for-sale investments158,646201,596Deferred tax assets3,4183,044Prepayments for acquisition of land use 9,652-1,574,3301,547,829Current assetsInventories401,543344,220Trade and other receivables9375,963314,353Prepaid lease payments on land use rights5,7414,070Amount due from immediate holding company-8,465Amounts due from fellow subsidiaries37-Tax recoverable1,289142Pledged bank deposits35,98037,496Bank balances and cash368,070364,3981,188,6231,073,144Assets classified as held for sale9,64615,3901,198,2691,088,534Current liabilitiesTrade and other payables10503,914491,698Amounts due to fellow subsidiaries6,087-Amount due to an associate2498Tax payable3,0617,069Borrowings200,000124,024713,064623,289Liabilities associated with assetsclassified as held for sale1,166-714,230623,289Net current assets484,039465,245Total assets less current liabilities2,058,3692,013,074Capital and reservesShare capital457,313457,313Reserves1,206,0431,164,324Proposed final dividend22,86622,866Equity attributable to owners of the Company1,686,2221,644,503Non-controlling interests38,01036,318Total equity1,724,2321,680,821Non-current liabilitiesDeferred tax liabilities2,87111,597Borrowings275,528270,000Deferred income55,73850,656334,137332,2532,058,3692,013,074NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNDER HKGAAP1. BASIS OF PREPARATIONThe audited consolidated financial statements are prepared in accordance with Hong Kong Financial Reporting Standards (HKFRSs), Hong Kong Accounting Standards (HKASs) issued by Hong Kong Institute of Certified Public Accountants (HKICPA) and the disclosure requirements of Appendix 16 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.2. APPLICATION OF NEW AND REVISED HKFRSsIn the current year, the Group has applied the following new and revised standards, amendments and interpretations (INT) (new and revised HKFRSs) issued by the Hong Kong Institute of Certified Public Accountants (the HKICPA).HKFRSs (Amendments)Amendments to HKFRS 5 as part of Improvements to HKFRSs 2008HKFRSs (Amendments)Improvements to HKFRSs 2009HKAS 27 (Revised)Consolidated and Separate Financial StatementsHKAS 39 (Amendment)Eligible Hedged ItemsHKFRS 1 (Revised)First-time Adoption of HKFRSs HKFRS 1 (Amendment)Additional Exemptions for First-time AdoptersHKFRS 2 (Amendment)Group Cash-settled Share-based Payment TransactionsHKFRS 3 (Revised)Business CombinationsHK INT 5Presentation of Financial Statements Classification by the Borrower of a Term Loan that Contains a Repayment on Demand ClauseHK (IFRIC) INT 17 Distributions of Non-cash Assets to Owners HKFRS 3 (Revised 2008) Business CombinationsThe Group applies HKFRS 3 (Revised) Business Combinations prospectively to business combinations for which the acquisition date is on or after 1 January 2010. The requirements in HKAS 27 (Revised) Consolidated and Separate Financial Statements in relation to accounting for changes in ownership interests in a subsidiary after control is obtained and for loss of control of a subsidiary are also applied prospectively by the Group on or after 1 January 2010.As there was no transaction during the current year in which HKFRS 3 (Revised) and HKAS 27 (Revised) are applicable, the application of HKFRS 3 (Revised), HKAS 27 (Revised) and the consequential amendments to other HKFRSs had no effect on the consolidated financial statements of the Group for the current or prior accounting periods.Results, of the Group in future periods, may be affected by future transactions for which HKFRS 3 (Revised), HKAS 27 (Revised) and the consequential amendments to the other HKFRSs are applicable.The Group has not early applied the following new and revised standards, amendments or interpretations that have been issued but are not yet effective.HKFRSs (Amendments)Improvements to HKFRSs 2010 except for the amendments to HKFRS 3 (Revised in 2008), HKFRS 7, HKAS 1 and HKAS 281 HKFRS 1 (Amendment)Limited Exemptions from Comparative HKFRS 7 Disclosures for First-time Adopters3HKFRS 1 (Amendment)Severe Hyperinflation and Removal of Fixed Dates for First-time Adopters5HKFRS 7 (Amendments)Disclosures Transfers of Financial Assets5HKFRS 9Financial Instruments7HKAS 12 (Amendment)Deferred Tax: Recovery of Underlying Assets6HKAS 24 (Revised)Related Party Disclosures4 HKAS 32 (Amendment)Classification of Rights Issues2HK(IFRIC) INT 14 (Amendment)Prepayments of a Minimum Funding Requirement4 HK(IFRIC) INT 19Extinguishing Financial Liabilities with Equity Instruments31 Effective for annual periods beginning on or after 1 July 2010 and 1 January 2011, as appropriate. 2 Effective for annual periods beginning on or after 1 February 2010.3 Effective for annual periods beginning on or after 1 July 2010.4 Effective for annual periods beginning on or after 1 January 2011.5 Effective for annual periods beginning on or after 1 July 2011.6 Effective for annual periods beginning on or after 1 January 2012.7 Effective for annual periods beginning on or after 1 January 2013.HKFRS 9 Financial Instruments issued in November 2009 and amended in October 2010 introduces new requirements for the classification and measurement of financial assets and financial liabilities and for derecognition.HKFRS 9 requires all recognised financial assets that are within the scope of HKAS 39 Financial Instruments: Recognition and Measurement to be subsequently measured at amortised cost or fair value. Specifically, debt investments that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortised cost at the end of subsequent accounting periods. All other debt investments and equity investments are measured at their fair values at the end of subsequent accounting periods.The most significant effect of HKFRS 9 regarding the classification and measurement of financial liabilities relates to the accounting for changes in fair value of a financial liability (designated as at fair value through profit or loss) attributable to changes in the credit risk of that liability. Specifically, under HKFRS 9, for financial liabilities that are designated as at fair value through profit or loss, the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is recognised in other comprehensive income, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss. Changes in fair value attributable to a financial liability's credit risk are not subsequently reclassified to profit or loss. Previously, under HKAS 39, the entire amount of the change in the fair value of the financial liability designated as at fair value through profit or loss was recognised in profit or loss.HKFRS 9 is effective for annual periods beginning on or after 1 January 2013, with earlier application permitted.The directors anticipate that HKFRS 9 that will be adopted in the Group's consolidated financial statements for the annual period beginning 1 January 2013 and that the application of the new standard will have a significant impact on amounts reported in respect of the Groups financial assets and financial liabilities. However, it is not practicable to provide a reasonable estimate of that effect until a detailed review has been completed.HKAS 24 Related Party Disclosures (as revised in 2009) modifies the definition of a related party and simplifies disclosures for government-related entities.The disclosure exemptions introduced in HKAS 24 (as revised in 2009) will affect the Group because the Group is a government-related entity. Although the Group conducted businesses with other government-related entities, the directors of the Company consider those government-related entities are independent third parties so far as the Groups business transactions with them are concerned. Therefore, the revised standards have no material impact on the Groups presentation.The directors of the Company anticipate that the application of the other new and revised standards, amendments or INTs will have no material impact on the results and the financial position of the Group. 3. SEGMENTAL INFORMATIONThe Groups operating segments, based on information reported to the board of directors of the Company, being the chief operating decision maker, for the purposes of resource allocation and assessment of segment performance focuses on the types of goods supplied. The principal types of goods supplied are bulk pharmaceuticals, preparations, chemical and other products and commerce circulations. The Groups reportable segments under HKFRS 8 are as follows:Bulk pharmaceuticals:Development, production and sales of bulk pharmaceuticalsPreparations:Development, production and sales of preparations (e.g. tablets and injections)Chemical and other products:Production and sales of chemical and other products Commerce circulations:Trading of pharmaceutical products (including retail and wholesale)Information regarding the above segments is reported below. Segment revenues and resultsThe following is an analysis of the Groups revenue and results by reportable segment.For the year ended 31 December 2010Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsEliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales1,312,077510,628686,48180,261-2,589,447Inter-segment sales5,672377,02095,704243,403(721,799)-Total 1,317,749887,648782,185323,664(721,799)2,589,447Segment profit 118,06720,3637,8937,716154,039Unallocated income26,698Unallocated expenses(39,138)Finance costs(17,892)Share of profits of associates5,260Profit before tax 128,967For the year ended 31 December 2009Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsEliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales1,219,263472,812599,0583,968-2,295,101Inter-segment sales3,447359,11571,390124,496(558,448)-Total 1,222,710831,927670,448128,464(558,448)2,295,101Segment profit 108,31525,1663,23512,483 149,199Unallocated income19,956Unallocated expenses(38,301)Finance costs(19,378)Share of profits of associates4,912Profit before tax 116,388The accounting policies of the reportable segments are the same as the Groups accounting policies. Segment profit represents the profit earned by each segment without allocation of investment and other income, other gains and losses, other expenses, depreciation for investment properties, financial costs and share of profits of associates. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and performance assessment. Inter-segment sales are charged at prevailing market rates.Segment assets and liabilitiesThe following is an analysis of the Groups assets and liabilities by reportable segment:At 31 December 2010Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Segment assets1,244,040428,056128,777342,3502,143,223Unallocated corporate assets629,376Consolidated assets2,772,599Segment liabilities282,263106,82644,90176,013510,003Unallocated corporate liabilities 538,364Consolidated liabilities1,048,367At 31 December 2009Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Segment assets1,214,283396,322112,451240,1871,963,243Unallocated corporate assets673,120Consolidated assets2,636,363Segment liabilities265,308115,39839,66071,830492,196Unallocated corporate liabilities 463,346Consolidated liabilities955,542For the purposes of monitoring segment performances and allocating resources among segments:all assets are allocated to reportable segments other than deferred tax assets, interest in an associate, available-for-sale investments, investment properties, tax recoverable, pledged bank deposits, bank balances and cash and assets classified as held for sale. Assets used jointly by reportable segments are allocated on the basis of revenues earned by individual reportable segments; andall liabilities are allocated to reportable segments other than deferred tax liabilities, borrowings, deferred income and tax payable. Liabilities for which reportable segments are jointly liable are allocated on the basis of revenues earned by individual reportable segments. Other segment informationFor the year ended 31 December 2010Amounts included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Addition to non-current assets (Note) 91,70631,86446589,057213,092Depreciation and amortisation81,05927,3371,27213,787123,455Reversal of impairment losses on trade receivables (413)(86)--(499)Impairment losses on other receivables138891,063-1,290Impairment losses on amounts due from fellow subsidiaries12,474---12,474Write-down of inventories6,3112,593-18,905Note: Non-current assets excluded financial instruments, deferred tax assets and interest in an associate.For the year ended 31 December 2010Amounts regularly provided to the chief operating decision maker but not included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Interest in an associate-16,620--16,620Interest income1,662690197 822,631Loss on disposal of property, plant and equipment9,5983,4237213,030Finance costs(13,084)(4,730)(77)(1)(17,892)Income tax expense(13,469)(3,367)(3,074)(2,249)(22,159)For the year ended 31 December 2009Amounts included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Addition to non-current assets (Note) 129,50648,346200109,556287,608Depreciation and amortisation83,43129,8299066,106120,272Reversal of impairment losses on trade receivables (196)(10)-(5)(211)Impairment losses on other receivables32286126-534Write-down of inventories234351359-944Note: Non-current assets excluded financial instruments, deferred tax assets and interest in an associate.Amounts regularly provided to the chief operating decision maker but not included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Interest in an associate-14,360--14,360Interest income1,265478381481,929Loss on disposal of property, plant and equipment11,4094,21012215,633Finance costs(13,765)(5,350)(261)(2)(19,378)Income tax expense(6,212)(2,930)(1,496)(2,370)(13,008)Geographical informationThe Groups customers are mainly located in the PRC, Europe, Americas and other countries. Revenues from external customersYear endedYear ended31/12/201031/12/2009RMB000RMB000PRC1,701,7541,448,559Europe319,414252,710Americas439,800421,997Others128,479171,8352,589,4472,295,101Over 99% of the Groups non-current assets are located in the PRC and therefore the analysis of non-current assets by geographical location of the assets is not presented.Information about major customersThe Groups customer base includes a wide range of different customers. In 2009 and 2010, the Group had no single customer contributed 10% or more of the Groups revenue and therefore no significant concentration of source of income from a particular customer.4. FINANCE COSTSYear endedYear ended31/12/201031/12/2009RMB000RMB000Interest on:- Bank loans wholly repayable within 5 years16,48616,403 Government loans not wholly repayable within 5 years1,11254917,59816,952Net foreign exchange (gain)/ loss on bank loans (1,263) 70Discount charges on bank acceptance notes1,5572,35617,89219,3785. INCOME TAX EXPENSEYear endedYear ended31/12/201031/12/2009RMB000RMB000PRC enterprise income tax - Current24,88625,234 - Over-provision in prior years-(2,676)24,88622,558 Deferred tax (2,727)(9,550)22,15913,008Under the Law of the PRC on Enterprise Income Tax (the EIT Law) and Implementation Regulation of the EIT Law, the tax rate of the PRC companies is 25% for both years. Pursuant to the relevant laws and regulations in the PRC, the Company was accredited as a high-tech enterprise. The accreditation is valid for three years. The Company is entitled to the preferential tax rate of 15% for a three-year period commencing from 1 January 2008 to 31 December 2010.Pursuant to the relevant laws and regulations in the PRC, two subsidiaries operating in the PRC are entitled to exemption from the PRC income tax in the first two years from the first profit-making year, followed by a 50% reduction of the PRC income tax for the next three years. 6. PROFIT FOR THE YEARProfit for the year has been arrived at after charging (crediting):Year endedYear ended31/12/201031/12/2009RMB000RMB000Depreciation for property, plant and equipment117,597115,527Depreciation for investment properties2,688394Amortisation of prepaid lease payments on land use rights5,7414,070Amortisation of technical know-how (included in administrative expenses)117675Total depreciation and amortisation126,143120,666Auditors remuneration1,1381,424Research and development costs recognised as an expense17,36819,714Operating lease rentals on land and buildings8821,016(Reversal) recognition of impairment losses on financial assetstrade receivables (499)(211)other receivables 1,290534amounts due from fellow subsidiaries 12,474-13,265323Impairment loss on assets classified as held for sale3,987-Write-down of inventories (included in cost of sales)8,905944Staff costs (excluding directors and supervisors emoluments) 238,510242,124Cost of inventories recognised as an expense2,108,5071,849,7387. DIVIDENDSYear endedYear ended31/12/201031/12/2009RMB000RMB000Dividends recognised as distribution during the year- 2009 final dividend: RMB0.05 (2009 : 2008 final dividend RMB0.03) per share 22,86613,719The final dividend of RMB0.05 (2009: RMB0.05) per share (approximately HK$0.059 (2009: HK$0.057) per share, including income tax of A shares) on 307,312,830 A shares and 150,000,000 H shares has been proposed by the directors of the Company and is subject to approval by shareholders at the Annual General Meeting and has been included as a dividend reserve in the consolidated financial statements.8. EARNINGS PER SHAREThe calculation of the basic earnings per share is based on the Groups profit for the year attributable to the owners of the Company of approximately RMB101,299,000 (2009: RMB99,687,000) and based on the weighted average number of 457,312,830 (2009: 457,312,830) shares in issue during the year.Basic earnings per share and diluted earnings per share for two years ended 31 December 2010 and 2009 are the same as there were no dilutive events existed during both years.9. TRADE AND OTHER RECEIVABLES31/12/201031/12/2009RMB000RMB000Trade and bills receivables308,235280,080Less : Allowance for doubtful debts of trade receivables(1,979)(7,603)306,256272,477Other receivables, deposits and prepayments78,83549,714Less : Allowance for doubtful debts of other receivables(9,128)(7,838)69,70741,876Total trade and other receivables375,963314,353As at 31 December 2010, included in the trade receivables approximately RMB80,819,000 (2009: RMB104,468,000) and approximately RMB15,274,000 (2009: RMB13,490,000) is denominated in United States Dollars (USD) and Euro (EUR) respectively.The Groups revenue from export sales is on letter of credit or documents against payment. The credit period is agreed upon in the sales contract. Except for some particular customers where payment in advance is normally required, the Group allows an average credit period of 30 days to its local trade customers and 90 days for local hospital customers. The following is an aged analysis of the trade and bills receivables net of allowance for doubtful debts of trade and bills receivables presented based on the invoice date at the end of the reporting period.31/12/201031/12/2009RMB000RMB000Within one year303,310270,571More than one year but less than two years2,6011,503More than two years but less than three years319403Over three years26-306,256272,477Included in the Group's trade and bills receivable balance are debtors with aggregate carrying amount of approximately RMB4,764,000 (2009: RMB3,951,000) which are past due as at the reporting date for which the Group has not provided for impairment loss. The Group does not hold any collateral over the balances. In respect of trade and bill receivables, individual credit evaluations are performed on all customers requiring credit over a certain amount. These evaluations focus on the customers past history of making payments when due and current liability to pay, and take into account information specific to the customer as well as pertaining to the economic environment in which the customers operate. 98% (2009: 99%) of the trade and bill receivables that are neither past due nor impaired have good settlement history under the Groups individual credit evaluations. The Group does not hold any collateral over these balances.Ageing of trade receivables which are past due but not impaired31/12/201031/12/2009RMB000RMB000Within one year2,7232,546More than one year but less than two years1,8171,136More than two years but less than three years212269More than three years12-Total4,7643,951Receivables that were past due but not impaired relate to a number of independent customers that have a good track record with the Group. Based on past experience, management believes that no impairment allowance is necessary in respect of these balances as there has not been a significant change in credit quality and the balances are still considered fully recoverable. The Group does not hold any collateral over these balances.Movements in the allowance for doubtful debts of trade receivables20102009RMB000RMB000At 1 January7,60311,498Impairment losses reversed(499)(211)Amounts recovered during the year120764Amounts written off as uncollectible(5,245)(4,448)At 31 December1,9797,603In determining the recoverability of trade receivables, the Group considers any change in the credit quality of the trade receivables from the date credit was initially granted up to the end of the reporting period. The concentration of credit risk is limited due to the customer base being large and unrelated.Included in the allowance for doubtful debts of trade receivable are individually impaired trade receivables with an aggregate balance of approximately RMB519,000 (2009: RMB150,000) which are long outstanding over 3 years. The Group does not hold any collateral over these balances.Movements in the allowance for doubtful debts of other receivables20102009RMB000RMB000At 1 January7,8387,436Impairment losses recognised 1,290534Amounts written off as uncollectible-(132)At 31 December9,1287,838Included in the allowance for doubtful debts of other receivables are individually impaired other receivables with an aggregate balance of approximately RMB9,128,000 (2009:RMB7,838,000) which are long outstanding over 3 years. The Group does not hold any collateral over these balances. 10. TRADE AND OTHER PAYABLES31/12/201031/12/2009RMB000RMB000Trade payables326,913280,334Other payables and accrued charges177,001211,364503,914491,698The following is an aged analysis of trade payables presented based on the invoice date at the end of the reporting period. 31/12/201031/12/2009RMB000RMB000Within one year311,497269,164More than one year but less than two years6,0484,987More than two years but less than three years3,630747Over three years 5,7385,436326,913280,334As at 31 December 2010, included in the trade payables of approximately RMB16,351,000 (2009: RMB19,981,000) is denominated in EUR.The average credit period on purchases of goods is approximately 45 days. The Group has financial risk management policies in place to ensure that all payables are settled within the credit timeframe.11. RELATED PARTY TRANSACTIONSExcept as disclosed in elsewhere in the consolidated financial statements, the other significant related party transactions, which were carried out in the normal course of the Groups business are as follows:Year endedYear ended31/12/201031/12/2009RMB000RMB000SXPGC:- Payment of annual trademark licence fee (1)1,1001,100- Rental expense500500- Consideration for acquisition of additional interests in subsidiaries (2)-636Fellow subsidiaries :- Sale of water, electricity, steam and waste materials10,82410,258- Purchase of raw materials64,40884,802- Rental income-134- Design fee income550 - Impairment losses on amounts due from fellow subsidiaries12,474-Associates :- Sale of water, electricity, steam and waste materials656-- Purchase of raw materials296,127- Design fee income-11Non-controlling interest shareholders :- Sale of bulk pharmaceuticals and chemical raw materials130,031144,926- Purchase of chemical raw materials838514Notes :On 7 December 1996, the Group was granted the exclusive right to use the trademark Xinhua (Trademark) by SXPGC for its existing and future products in and outside the PRC at an initial annual fee of RMB600,000 increasing at the rate of an extra RMB100,000 per year until the annual fee reaches the cap amount of RMB1,100,000, which shall stay as such until the agreement is terminated. The terms of the agreement shall continue to have effect during the validity period of the Trademark, being 28 February 2013, subject to further renewal of the registration of the Trademark. During the year ended 31 December 2010, the annual fee paid by the Group amounting RMB1,100,000 (2009: RMB1,100,000).During the year ended 31 December 2009, the Company acquired additional interests of subsidiaries from SXPGC at consideration of RMB636,000.The Group operates in an economic environment predominated by enterprises directly or indirectly owned or controlled by the PRC government through its numerous authorities, affiliates or other organisations (collectively State-owned Enterprises). During the year ended 31 December 2010, the Group had transactions with State-owned Enterprises including, but not limited to, sales of pharmaceutical products and purchases of raw materials. The directors of the Company consider that transactions with other State-owned Enterprises are activities in the ordinary course of business, and that dealings of the Group have not been significantly controlled or owned by the PRC government. The Group has also estabq s t  x z . 0 2 4 T V X ٿ٭lSl77h654hm5B*CJOJPJQJ\aJnHphtH1h654hmB*CJOJPJQJaJnHphtH%h654hmB*CJOJQJaJphh654hmCJOJQJaJh654hmCJOJQJaJh654hm5CJOJQJaJ"h654hm5CJOJQJaJo(2jh654hm5CJOJQJUmHnHo(uh654hm5CJOJQJo(+h654hm6KHOJPJQJaJnHtHq r s u v  x 2 X rs!"78ij^T^`^ $dT^a$ $UDb]a$$a$>CX \ ` b  eop˯頍ttY>%1h654htB*CJOJPJQJaJnHphtH4h654htB*CJOJPJQJaJnHo(phtH4h654hfyB*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH%h654hmB*CJOJQJaJphh654hmB*OJQJph7h654hm5B*CJOJPJQJ\aJnHphtH:h654hfy5B*CJOJPJQJ\aJnHo(phtH+h654hm5B*CJOJQJ\aJphpQprs ̹幠j[@4h654h>HB*CJOJPJQJaJnHo(phtHh654hmCJOJQJaJ4h654h=NhB*CJOJPJQJaJnHo(phtH4h654hB*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH%h654hmB*CJOJQJaJph1h654htB*CJOJPJQJaJnHphtH4h654htB*CJOJPJQJaJnHo(phtH !"8<Fijθθ~bNA3h654hm5CJ\aJh654hmCJKHaJ&h654hm5CJPJ]aJnHtH7h654hm5B*CJOJPJQJ\aJnHphtH7h654hm5B*CJOJPJQJ\aJnHphtH:h654h>H5B*CJOJPJQJ\aJnHo(phtH+h654hm5B*CJOJQJ\aJphh654hmCJOJQJaJh654hmCJOJQJaJ%h654hmB*CJOJQJaJphmb $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la$1$IfWDd` $$1$Ifa$ ȷ{gY{YG:h654hiCJKHaJ#h654hiCJPJaJnHo(tHh654hm6CJ]aJ&h654hm6CJPJ]aJnHtH#h654hmCJPJaJnHo(tH#h654hCJPJaJnHo(tHh654hmCJaJh654hmCJKHaJ h654hm56CJ\]aJ&h654hm5CJPJ\aJnHtHh654hm5CJ\aJ)h654h5CJPJ\aJnHo(tHxm $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la$$1$Ifa$gdi#$%.?@ST]nǫ̻̻םזc7h654hm5B*CJOJPJQJ\aJnHphtHh654hiaJh654hiPJnHo(tH h654hih654hRCJaJ$h654hiCJKHPJaJnHtH h654hiCJPJaJnHtHh654hiCJaJh654hiCJKHaJh654hiCJKHaJh654hi5CJKHaJ"%.7?{mmm$$1$Ifa$gdi $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la?@T]fn{mmm$$1$Ifa$gdi $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 lano{mmm$$1$Ifa$gdi $$1$Ifa$xkd*$$Ifl,\3 EW! p9!644 laqccc$$1$Ifa$gdiv$ $Ifa$xkd$$Ifl,\3 EW! p9!644 laooooJ%<TPL HD@< ^TQ ^xkdB$$Ifl,\3 EW! p9!644 laտmO1:h654hm5B*CJOJPJQJ\aJnHo(phtH:h654h*O5B*CJOJPJQJ\aJnHo(phtH:h654hs5B*CJOJPJQJ\aJnHo(phtH+h654hm5B*CJOJQJ\aJph:h654hi5B*CJOJPJQJ\aJnHo(phtH+h654h]4fCJOJPJQJaJnHo(tH+h654hmCJOJPJQJaJnHo(tH(h654hmCJOJPJQJaJnHtH#+19@H;$1$IfWD`; $$1$Ifa$%<TPL HD@< ^.<TPL HD@< WD^`gd`)F  "#*+./0189<=?ǹ{p^JH5B*CJOJPJQJ\aJnHo(phtH1h654hmB*CJOJPJQJaJnHphtHh654h?|CJaJh654h?|CJKHPJaJ ./0opaYPP^gd`)F & Fgds%<TPL HD@< ^xkd$$Ifl,\S "b :::"644 la] $$Ifa$gd*$$1$Ifa$gd=$$1$Ifa$gd* $$1$Ifa$%<TPL HD@< ^ ĭ{m{Y{{mLY9$h654h(:CJKHPJaJnHtHh654h=CJKHaJ'h654h(:CJKHPJaJnHo(tHh654h=6CJ]aJ'h654h=CJKHPJaJnHo(tHh654h=CJKHaJ h654h=56CJ\]aJ,h654h=56CJPJ\]aJnHtH-h654h=5CJKHPJ\aJnHo(tHh654h=5CJKH\aJ'h654h=5CJKHPJaJnHtHpbTTTH $$Ifa$gd(:$$1$Ifa$gd(:$$1$Ifa$gdykd>$$Ifl4r&*p#tG?644 laf4 7FUhi!'6EZ[ʷʤ{na{{naM'h654h(:5CJKHPJaJnHtHh654hM|CJKHaJhRhM|CJKHaJh654hM|CJKHaJh654hM|5CJKHaJh654hM|CJKHaJo($h654hM|CJKHPJaJnHtH$h654h(:CJKHPJaJnHtHh654h(:CJKHaJhRh(:CJKHaJh654h(:CJKHaJh654h(:5CJKHaJ 7FUZhseWWWK $$Ifa$gd(:$$1$Ifa$gd(:$$1$Ifa$gdykd$$Iflr&*p#tG?644 lahiseWWWK $$Ifa$gd(:$$1$Ifa$gd(:$$1$Ifa$gdVkd$$Iflr&*p#tG?644 la'6ELZseWWWK $$Ifa$gd(:$$1$Ifa$gd(:$$1$Ifa$gdVkd]$$Iflr&*p#tG?644 laZ[seYKKY$$1$Ifa$gd(: $$Ifa$gd(:$$1$Ifa$gdykd $$Iflvr&*p#tG?644 laseWKW=$$1$Ifa$gd(: $$Ifa$gd(:$$4$Ifa$gd(:$$1$Ifa$gd3kd $$Iflvr&*p#tG?644 la=>?LN_pɶ|n|aTA-A'h654hX5CJKHPJaJnHo(tH$h654hM|CJKHPJaJnHtHh654hyCJKHaJhRhyCJKHaJh654hy5CJKHaJh654hyCJKHaJ$h654hyCJKHPJaJnHtHh654h(:CJKHaJhRh(:CJKHaJ$hRh(:CJKHPJaJnHtHh qh(:CJKHaJ'h qh(:CJKHPJaJnHo(tH*h654h(:5CJKHPJaJnHo(tH#:>?NK=$$1$Ifa$gdykdv $$Iflvr&*p#tG?644 la $$Ifa$gd(:$$4$Ifa$gd(:$$1$Ifa$gd3N_puK=$$1$Ifa$gdykd) $$Iflr&*p#tG?644 la$$1$Ifa$gdy$$1$Ifa$gdX $$Ifa$gdX ):;<=PT˽dFd2'h654h!f05CJKHPJaJnHtH:h654hC5B*CJOJPJQJ\aJnHo(phtH:h654hU95B*CJOJPJQJ\aJnHo(phtH'h654hyCJKHPJaJnHo(tHh654hyCJKHaJhRhyCJKHaJh654hyCJKHaJh654hy5CJKHaJ$h654hyCJKHPJaJnHtH$h654hM|CJKHPJaJnHtHh654hM|CJKHaJo( K=$$1$Ifa$gdykd $$Iflr&*p#tG?644 la$$1$Ifa$gdy$$1$Ifa$gdX $$Ifa$gdX )+:;<=WNA ^`gdU9^gdU9kd $$Iflr&*p#tG?644 la$$1$Ifa$gdy$$1$Ifa$gd44=OPUZ^cg $$Ifa$gd44$$1$Ifa$gd44$$1$Ifa$gd=!w ^`gdU9 TUWZ]acfgijq^K=0h654hU9CJKHaJh654hU95CJKHaJ$h654hU9CJKHPJaJnHtH$h654h44CJKHPJaJnHtH$h654h44CJKHOJQJ^JaJh654h446CJ]aJ'h654h44CJKHPJaJnHo(tHh654h44CJKHaJ h654h4456CJ\]aJ-h654h445CJKHPJ\aJnHo(tHh654h445CJKH\aJ'h654h44CJKHOJQJ^JaJo(aVHHHH$$1$Ifa$gd=!w $1$Ifgd=!wkdB$$Ifr$3$4 ap2aVHHHH$$1$Ifa$gd=!w $1$Ifgd=!wkd,$$Ifr$3$4 ap2(,-2CDDǹ홅whhUA'h654hCCJKHPJaJnHo(tH$h654hCCJKHPJaJnHtHh654hU9CJKHQJaJh654hU9CJKHaJo('h654h!f0CJKHPJaJnHo(tH$h654htCJKHPJaJnHtHh654hU9CJKHaJh654hU95CJKHaJ$h654hU9CJKHPJaJnHtH$h654h44CJKHPJaJnHtH$h654hU9CJKHOJQJ^JaJ-27>CaVHHHH$$1$Ifa$gd=!w $1$Ifgd=!wkd$$Ifr$3$4 ap2CDFPaVHH9H$$1$4$Ifa$gdC$$1$Ifa$gd=!w $1$Ifgd=!wkd $$Ifr$3$4 ap2DFNPR˸zgS@$h654h!f0CJKHPJaJnHtH'h654hCCJKHPJaJnHo(tH$h654hCCJKHPJaJnHtHh654hU95CJKHaJh654hU9CJKHaJh654hU9CJKHQJaJ'h654h!f0CJKHPJaJnHo(tH$h654htCJKHPJaJnHtH$h654hU9CJKHOJQJ^JaJh654hyCJKHaJ'h654hU9CJKHPJaJnHo(tHPRaVHHHH$$1$Ifa$gd=!w $1$Ifgd=!wkd$$Ifr$3$4 ap2aVHHHH$$1$Ifa$gd=!w $1$Ifgd=!wkd$$Ifr$3$4 ap2  ^_ҿ}iS}F3F$h654h44CJKHPJaJnHtHh654h44CJKHaJ*h654hC5CJKHPJaJnHo(tH'h654hC5CJKHPJaJnHtH'h654h445CJKHPJaJnHtH3h654h44CJKHOJPJQJ^JaJnHo(tH'h654h!f05CJKHPJaJnHtH$h654hU9CJKHOJQJ^JaJh654hU9CJKHaJh654hU95CJKHaJ$h654hU9CJKHOJQJ^JaJ aSEE9E $$Ifa$gd44$$4$Ifa$gd44$$1$Ifa$gd=!wkd$$Ifr$3$4 ap2 D[_`9kd$$Ifr$3$4 ap2 $$Ifa$gd44$$1$Ifa$gd44$$4$Ifa$gd44_`tƲƤƐ}obO9+h654hB\CJOJPJQJaJnHo(tH$h654hU9CJKHOJQJ^JaJh654hU9CJKHaJh654hU95CJKHaJ$h654hU9CJKHPJaJnHtH'h654hM|CJKHPJaJnHo(tHh654hM|CJKHaJo('h654hCJKHPJaJnHo(tH$h654hM|CJKHPJaJnHtH'h654h&SCJKHPJaJnHo(tH$h654h44CJKHOJQJ^JaJ`HFFkd$$Ifr$3$4 ap2$$1$Ifa$gd=!w $1$Ifgd=!wJNY]^_dif`kd$$If4FLt%u<d&    4 ahf4 $$Ifa$"6TPL HD@<%^T^` 04:N\]_acdghinɺt`N$B$C$^$`$a$e$x${$|$$$$$$$$$$$$$$$$$$$$%%%%A%C%M%h%%%%%%%%%%주׼׼죐%h654hNB*CJOJQJaJph1h654h-/B*CJOJPJQJaJnHphtH4h654h-/B*CJOJPJQJaJnHo(phtH(h654h-/B*CJOJQJaJo(ph%h654h-/B*CJOJQJaJph8%%%%%&&& &&*&<&?&@&C&&&&&&&&&&''' '+'7'9';'<'주주w\w\w4h654hB*CJOJPJQJaJnHo(phtH%h654hB*CJOJQJaJph1h654hmB*CJOJPJQJaJnHphtH1h654h-/B*CJOJPJQJaJnHphtH(h654h-/B*CJOJQJaJo(ph4h654h-/B*CJOJPJQJaJnHo(phtH%h654h-/B*CJOJQJaJph <'@'D'|'~'''''''''''''''''(( (((7(C(((((((((!)˸˸˸˸˸ˣˣw\w4h654hBB*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJph1h654hmB*CJOJPJQJaJnHphtH(h654hB*CJOJQJaJo(ph%h654hB*CJOJQJaJph4h654hB*CJOJPJQJaJnHo(phtH1h654hB*CJOJPJQJaJnHphtH$!)$)&)()>)?)@)C)G)))))))))*****ҷҷҷҷzhR7Ҟ74h654h^@B*CJOJPJQJaJnHo(phtH+h654hmCJOJPJQJaJnHo(tH"h654hm5CJOJQJ\aJ(h654hmCJOJPJQJaJnHtHh654hmCJOJQJaJ1h654hmB*CJOJPJQJaJnHphtH4h654h|+B*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJph4h654h-/B*CJOJPJQJaJnHo(phtH********y****++++++++ +!+"+Z+++ҷҜҁҁfҜҷҜM1h654hmB*CJOJPJQJaJnHphtH4h654hC*B*CJOJPJQJaJnHo(phtH4h654hT%B*CJOJPJQJaJnHo(phtH4h654h^@B*CJOJPJQJaJnHo(phtH4h654hmB*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJph4h654h-/B*CJOJPJQJaJnHo(phtH)2+3+++,,--..J/K///506000>1?1Z4[4o4p4#7$7 $`a$gd$a$gd^++++;,>,?,B,F,G,H,\,^,y,,,,,,,,,,,,,,-----پپپ٣پo٣پي٣پيZ)h654hmB*CJOJPJQJaJph4h654h(B*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH4h654hmB*CJOJPJQJaJnHo(phtH4h654h^@B*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJph%h654h-/B*CJOJQJaJph------... .....#./.1.3.4...ʱʃʱhMM41h654h%ynB*CJOJPJQJaJnHphtH4h654h%ynB*CJOJPJQJaJnHo(phtH4h654h;FB*CJOJPJQJaJnHo(phtH4h654hY?B*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJph1h654hmB*CJOJPJQJaJnHphtH4h654hmB*CJOJPJQJaJnHo(phtH4h654h B*CJOJPJQJaJnHo(phtH... //J/_/a/w/////////////001030405060a0b0c0d0f0ʱ垱ʞn垉S4h654h;FB*CJOJPJQJaJnHo(phtH4h654hr:B*CJOJPJQJaJnHo(phtH(h654hmB*CJOJQJaJo(ph%h654hmB*CJOJQJaJph1h654hmB*CJOJPJQJaJnHphtH4h654hmB*CJOJPJQJaJnHo(phtH4h654h%ynB*CJOJPJQJaJnHo(phtH f0000000,1<1>1?111111111111g2k223z3}3L4P4ѾѾoTT4h654h3,B*CJOJPJQJaJnHo(phtH4h654hmB*CJOJPJQJaJnHo(phtH4h654hhsB*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH%h654hL9!B*CJOJQJaJph4h654hL9!B*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJphP4Y4Z4o4p44455.5855555{66$7(7V7Y7e7i777888888888,9-9\9_9h9i9m999999999996:7:©h654hPJaJnHo(tHh654haJo(h654haJ1h654hmB*CJOJPJQJaJnHphtHh654hmCJOJQJaJ4h654hmB*CJOJPJQJaJnHo(phtH%h654h7DB*CJOJQJaJph4$777,9-999::;;O<P<??`@a@@@ZB[BEE[E\EFGGGG $`a$gd$a$gd7:::);.;4;9;L;u;;;;;;;;;;<<<<.<2<3<8<E<L<M<O<P<<<\=m===>">(>3>>>>>DHDMDSDTD_D`DkDlDyDzDDDDDDDǿշշտh654ho(h654hH*h654hPJnHo(tH h654hh654hPJaJnHo(tHh654haJh654haJo(HDDDDDDDDDEEEEEEEE%E.E[E\EbEEEEEEE)F*F7F9FXFYFFFFGGGMGYGZG`GiGmGqGGGHHHHHHHHHHHHHH$I(I2I6IIIIIIIIIIIIJJ Jh654hPJaJnHtHh654haJh654haJo(h654hPJaJnHo(tH h654hNGGHHIITJUJ`MaMnMoMOORRRRaSbSTUVVWWgdgd^gd $`a$gd$a$gd JAJIJSJUJJJJJJ KK9KKKKK$L2L8LgLoLLM M"M1M`MaMoMMMMMMMMMNNNNMNiNwNzNNN)O9OMONOOOOO PPSPTPUPVPPPPh654hCJOJQJaJ4h654hB*CJOJPJQJaJnHo(phtHh654hPJaJnHtHh654hPJaJnHo(tHh654haJo(h654haJ@PPPPPPQQ.Q6QdQeQfQgQQQQQQQKR`RlRsR{RRRRRRRRRRR)S/SDSKS`SaSbSSSTTTTTTTUUU_VcVVVVV\W]WWWWW?XVXbXfX|X}X~XXXXXXsY h654hh654hPJnHo(tHh654hPJaJnHo(tHh654haJh654haJo(NW}X~XXXZZ8\9\G]H]]]__lama/c0cccddffggg$1$7$8$H$a$gd$a$gdsYtYYYYYYYYYZZZZZCZRZWZ[Z\Z]ZZZ][d[f[m[t[[[[[[[[[[[[[\ \\\\\7\8\9\T\`\d\m\x\y\\\]]]]G]H]K]T]U]u]]]]]]]]]]]h654hH*h654hOJQJo(h654hPJnHo(tHh654hnH o(tH h654hh654ho(L]]]^^_ _=_C_b_r________)`.`A`R`Z`\`|``````````a.akalamasaaaaaaaaaaaaaaaabb&b+b8bIbub|bbbbbc/dYd˿˿˿˿˯˿˿˿˿˿˿h654hKHPJnH o(tH h654hKHPJo(h654hKHPJh654hnH o(tH h654hh654hPJnHo(tHh654ho(EYdbdedfdpdqdtd}dddddddddAeBeNeYe_eneeeeeee f f%f.f2f6fffnfffffffggggKgLgVg_gggggghhLhPhbhchhhhhhhhhhsitiiiih654hnH o(tH h654hh654hPJnHo(tHh654ho(h654hKHPJo(h654hKHPJJgghhqjrjjjkkm m m m!m8m9mmmnnnnoo^ ^` +gdygd>$a$gd-/$a$gdiiiiiij'jSjbjcjdjejmjqjrjjjjj_k`kfkpkkkkk&lClglqlllmm m mmm m!m9mm.h654hm5CJOJPJQJ\aJnHtH+h654hyCJOJPJQJaJnHo(tHh654hmCJOJQJaJ+h654hq'CJOJPJQJaJnHo(tHh654h-/PJnHo(tHh654hPJnHo(tH h654hh654ho(h654hA PJnHo(tH h654hA *9m=mEmmmnn-n/n2ntnvnwnnnnnnnnnnnoo읂인j[h654hmCJOJQJaJ.h654hm5CJOJPJQJ\aJnHtH4h654hr:B*CJOJPJQJaJnHo(phtH4h654hmB*CJOJPJQJaJnHo(phtH4h654hdB*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH%h654hmB*CJOJQJaJpho"o)o*o=o@ogohorotoxoyo|oooʱʖjOjO<%h654h%B*CJOJQJaJph4h654h%B*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH%h654hmB*CJOJQJaJph4h654hD B*CJOJPJQJaJnHo(phtH1h654hvbB*CJOJPJQJaJnHphtH4h654hvbB*CJOJPJQJaJnHo(phtH4h654hx8B*CJOJPJQJaJnHo(phtHoooo,p.ppBpCpEpGpHpـrdVA,)h=~hm5CJPJ\aJnHo(tH)h=~hd5CJPJ\aJnHo(tHh=~hm5CJ\aJh654hmPJnHo(tHh654h!IPJnHo(tH(h654hmCJOJPJQJaJnHtH1h654hL/5CJOJPJQJ\aJnHo(tH"h654hm5CJOJQJ\aJ1h654hm5CJOJPJQJ\aJnHo(tHh654hmCJOJQJaJ.h654hm5CJOJPJQJ\aJnHtHooo=p>pCpHpQpWp_p$V$If^V`a$$V$If^V`a$gd!I$T^T`a$gdCT^T` ^` HpIpPpQpTpUpVpWp^p_p`ppppppq°}r\TMD4Dh654hhPJaJnHo(tHh654hhaJ h654hmh=~hm5+h654hm5B*CJOJQJ\aJphh654hmnHtH h654hmCJPJaJnHtH&h654hm6CJPJ]aJnHtHh654hm6CJ]aJ#h654hdCJPJaJnHo(tHh654hmCJaJh=~hm5nHtH h=~hm56CJ\]aJ)h=~hm56CJPJ]aJnHtH_p`pppppzzee$V$If^V`a$&6TPL HD@<{$If^]kd3$$IflF! $  !    4 la ppq qqrd$$1$Ifa$gdX$$1$Ifa$gdy v${$IfVDFWDj^`a$gdM]kd$$IflF! $  !    4 la qqqq qqq/q6q=q>q?qgqlqmqrqsqtqqqqqqqqqqqqqqqqqqqδnjzΌnznzn`h=~hh5CJaJo(h654hhCJaJo(#h654hhCJPJaJnHo(tH h654hhCJPJaJnHtHh654hhCJaJh=~hh5CJaJ$h654hhCJKHPJaJnHtH h654hhh654hhCJKHaJ*h=~hh5CJKHPJaJnHo(tHh=~hh5CJKHaJ#qq/q6q=qzl$$1$Ifa$gdX$$1$Ifa$gdyVi$IfVD$WD2^V`igdM]kd'$$IflF! $  !    4 la =q>qgqmqsqzl$$1$Ifa$gdX$$1$Ifa$gdy.$IfVDPWD^`.gdM]kd$$IflF! $  !    4 la sqtqqqqzl$$1$Ifa$gdX$$1$Ifa$gdyVi$IfVD$WD2^V`igdM]kd'$$IflF! $  !    4 la qqqqqzl$$1$Ifa$gdX$$1$Ifa$gdyVi$IfVD$WD2^V`igdM]kd$$IflF! $  !    4 la qqqqq||#$d$Ifa$gdf*&d$IfWD^&`gdM]kd'$$IflF! $  !    4 la qqqqqrrrrr r rrOrPrRrVrWrgrhrirjrƹƹ͉ueUB; h654hpL$h654hpLOJPJQJaJnHtHh=~hpL5CJOJQJaJh654hpL5CJKH\aJ'h654hhCJKHPJaJnHo(tHh654hhCJaJh654hhCJaJh=~hh5CJKHaJh=~hh5CJaJh654hhCJKHaJ h654hh h654hhCJPJaJnHtHh=~hh5CJaJo(&h=~hh5CJPJaJnHo(tHqqrrrzl$$1$Ifa$gdX$$1$Ifa$gdyVi$IfVD$WD2^V`igdM]kd$$IflF! $  !    4 la r rPrRrVrzl$$1$Ifa$gdX$$1$Ifa$gdyd\$IfVDPWD8^d`\gdM]kd' $$IflF! $  !    4 la VrWrgrhrirq$d$Ifa$gd[<$d$Ifa$gdyV$If^V`]kd $$IflF! $  !    4 la irjrrrryj$d$Ifa$gd[<$d$Ifa$gdyVi$IfVD$WD2^V`igdU]kd'!$$IflF! $  !    4 la jrlrrrrrrrrrrrrrrrrrr/s7s?s@sdsͿ󸚄taK*h=~hpL5CJKHPJaJnHo(tH$h654hpLOJPJQJaJnHtHh=~hpL5CJOJQJaJ*h654hpL5CJKHPJ\aJnHtHh654hpL5CJKH\aJh=~hpL5CJKHaJ h654hpLh654hpLOJQJaJo(.h=~hpL5CJOJPJQJaJnHo(tHh654hpLCJKHaJo(h654hpLCJKHaJrrrrr{m$$1$Ifa$gdX$$1$Ifa$gdyVi$IfVD$WD2^V`i_kd!$$IflF! $  !    4 la rrrrr}o$$1$Ifa$gdX$$1$Ifa$gdyVi$IfVD$WD2^V`i]kd+"$$IflF! $  !    4 la rrrrrq$d$Ifa$gd[<$d$Ifa$gdyV$If^V`]kd"$$IflF! $  !    4 la rr/s7s?s}o$$1$Ifa$gdX$$1$Ifa$gdy$IfVDIWDj^`]kd+#$$IflF! $  !    4 la ?s@sesisms}o$$1$Ifa$gdX$$1$Ifa$gdy$IfVDIWDj^`]kd#$$IflF! $  !    4 la dsesismsnsossssIthttttttǵlQl6l6l4h654hmB*CJOJPJQJaJnHo(phtH4h654hRB*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJphh654hmOJQJ%h654hmB*CJOJQJaJph/h654hm5B*OJPJQJ\nHphtH#h654hm5B*OJQJ\phh654hpLaJh654hpLCJKHaJh=~hpL5CJKHaJ'h654hpLCJKHPJaJnHo(tHmsnsss u uuuuuv|ztddbttt$d^`a$^%6TPL HD@<{d<^]kd+$$$IflF! $  !    4 la  ttttttttt u u u uuDuHuuuvvvҷҞ҃Ҟj[@ҞҞ4h654hlB*CJOJPJQJaJnHo(phtHh654hmCJOJQJaJ1h654hzg5CJOJPJQJ\aJnHo(tH4h654h!B*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH4h654hmB*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJph4h654hHB*CJOJPJQJaJnHo(phtHvvvvvvvvvvvvvvvwwPwhwwwxxxyyyyyyYzZzvzzҹҹҹҞ҆wҹҹwҹ҆w҆wd%h654hlB*CJOJQJaJphh654hmCJOJQJaJ.h654hm5CJOJPJQJ\aJnHtH4h654hmB*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH%h654hmB*CJOJQJaJph4h654hlB*CJOJPJQJaJnHo(phtH!vvww}x~xxxyyyyyyYzZzuzvzzzzz||O}P}^gdl^ d^`zzzzzzzz{{"{#{r{{{{{{{{*|뿰oT94h654hB*CJOJPJQJaJnHo(phtH4h654h]$B*CJOJPJQJaJnHo(phtH(h654hmB*CJOJQJaJo(ph1h654hmB*CJOJPJQJaJnHphtH%h654hmB*CJOJQJaJphh654hmCJOJQJaJ1h654hm5CJOJPJQJ\aJnHo(tH%h654hlB*CJOJQJaJph(h654hlB*CJOJQJaJo(ph*|+|<|>|d|f||||||||||||||||}}} }}}O}P}ҽҤҽҤҤҤ変nY(h654hmCJOJPJQJaJnHtH4h654h|B*CJOJPJQJaJnHo(phtH4h654hmB*CJOJPJQJaJnHo(phtH1h654hmB*CJOJPJQJaJnHphtH(h654hmB*CJH*OJQJaJph%h654hmB*CJOJQJaJph4h654hlB*CJOJPJQJaJnHo(phtHP}g}h}~~~34$$1$Ifa$gdT T^$^a$gdk$a$gdk ^`^d P}g}h}}}~~34PQcsͲ͙lVl>.h654h M5CJOJPJQJaJnHo(tH+h654h5CJOJPJQJaJnHtH.h654h5CJOJPJQJaJnHo(tH(h654hmCJOJPJQJaJnHtH1h654hm5;CJOJPJQJ\aJnHtH4h654hXB*CJOJPJQJaJnHo(phtH%h654hmB*CJOJQJaJphh654hmCJOJQJaJ h654hm@CJOJQJaJsu¬nZDZ4)nh654h<_2CJKHh654h<_2CJKH\aJo(*h654h<_2CJKHPJ\aJnHo(tH'h654hXCJKHPJaJnHo(tH'h654h<_2CJKHOJQJ\^JaJ&h654h<_25CJKHOJQJaJo(+h654hmCJOJPJQJaJnHo(tH+h654h,CJOJPJQJaJnHo(tH+h654hCJOJPJQJaJnHo(tHh654hm5CJOJQJaJ.h654hX5CJOJPJQJaJnHo(tH|nnnn$$1$Ifa$gdT $1$IfgdTwkd$$$Ifl4TF #& &J& #6    44 lagp˵~jWC0j$h654hXCJKHPJaJnHtH'h654hJ0CJKHPJaJnHo(tH$h654hJ0CJKHPJaJnHtH'h654h<_2CJKHPJ\aJnHtHh654hXCJKHaJ'h654hX5CJKHPJaJnHtH*h654hJ05CJKHPJaJnHo(tH*h654ha5CJKHPJaJnHo(tH*h654h<_25CJKHPJ\aJnHtHh654hX5CJKH\aJh654hX5CJKHaJ!WL@@2$$1$Ifa$gdX $$Ifa$gdX $1$IfgdTkd%$$Ifl4Tr +# &&&&#644 lagp234QtuÀĀՀր'(9:^_zЁ߁0?@OPpqԮԮԮԮԮԮԮԮԮԮԮԮԮԮh654hXCJKHaJh654hXCJKHh654hXCJKH\aJ&h654hX5CJOJQJ^JaJo(#h654hX5CJOJQJ^JaJh654hX5CJaJo($h654hXCJKHPJaJnHtHh654h<_2CJKH5!34QcK6* $$Ifa$gdXL$1$IfWD^L`gdTkd&$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdXcu?4 $1$IfgdTkd'$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX $$Ifa$gdXĀր?kd($$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX $$Ifa$gdX(:L^$$1$Ifa$gdX $$Ifa$gdX $1$IfgdT^_zYNBB4$$1$Ifa$gdX $$Ifa$gdX $1$IfgdTkd)$$IflTr +#& &&&&#644 lagp2ЁK@44 $$Ifa$gdX $1$IfgdTkd*$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX'0K@/ $1$IfWD` gdT $1$IfgdTkd+$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX0@P`pq?kd,$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX $$Ifa$gdXqȂ$$1$Ifa$gdX $$Ifa$gdX $1$IfWDp^ `gdTȂɂՂւMQmnăŃЃу!"/0LMapq˄̄لڄ !/0NOXպՖպպպպպh654hXCJKH\aJh654hX5CJKHaJo(&h654hX5CJOJQJ^JaJo(h654hX5CJaJo(h654hXCJKHaJ$h654hXCJKHPJaJnHtHh654hXCJKHh654hXCJKHaJ5ȂɂYNBB4$$1$Ifa$gdX $$Ifa$gdX $1$IfgdTkd.$$IflTr +#& &&&&#644 lagp2MOQ_K6 $1$IfWDp^ `gdTkd/$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX_mnK@44 $$Ifa$gdX $1$IfgdTkd 0$$IflXr +#& &&&&#644 lagp2$$1$Ifa$gdXăŃK6 $1$IfWDp^ `gdTkd/1$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX"0>LM?kd>2$$Iflr +# &&&&#644 lagp2$$1$Ifa$gdX $$Ifa$gdXMaq$$1$Ifa$gdX $$Ifa$gdX $1$IfgdT̄ڄYD88 $$Ifa$gdXD$1$IfWD^`DgdTkdM3$$IflTr +#& &&&&#644 lagp2ڄK6 $1$IfWDp^ `gdTkd\4$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX!0?NO?kdk5$$IflXr +#& &&&&#644 lagp2$$1$Ifa$gdX $$Ifa$gdXXYąŅ߅;IJXYwxφІنچ#$%&'NOivwҾҾҾҾҾҾҾҾҾpҾҾ&h654hu5CJPJaJnHo(tH'h654hO.CJKHPJaJnHo(tHh654hXCJKH\aJh654hXCJKHh654hXCJKHaJ&h654hX5CJOJQJ^JaJo(h654hX5CJaJo($h654hXCJKHPJaJnHtHh654hXCJKHaJ,Oą$$1$Ifa$gdX $$Ifa$gdX $1$IfWD^` gdTąŅ߅YNBB4$$1$Ifa$gdX $$Ifa$gdX $1$IfgdTkdz6$$IflXr +#& &&&&#644 lagp2;JYK@44 $$Ifa$gdX $1$IfgdTkd7$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdXYhwxK@4 $$Ifa$gdX $1$IfgdTkd8$$IflXr +#& &&&&#644 lagp2$$1$Ifa$gdXφІ?kd9$$IflXr +#& &&&&#644 lagp2$$1$Ifa$gdX $$Ifa$gdXІ$'7N$$1$Ifa$gdX $$Ifa$gdX$1$IfWD ^`gdTNOiwyYNB44$$1$Ifa$gdX $$Ifa$gdX $1$IfgdTkd:$$IflTr +#& &&&&#644 lagp2wy FNPZrtȈ<>^`ŵwcwIwI2h654hX5CJOJPJQJ^JaJnHo(tH&h654hX5CJOJQJ^JaJo(h654hX5CJaJo(h654hXCJKHQJaJo(h654hXCJKH\aJ"h654hXCJKHQJ\aJo(h654hX5CJKH\aJ$h654hXCJKHPJaJnHtHh654hXCJKHh654hXCJKHaJh654hX5CJKHaJo(K@ $1$IfgdTkd;$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdX FPZYD8*$$1$Ifa$gdX $$Ifa$gdX $1$IfWD^` gdTkd<$$IflTr +#& &&&&#644 lagp2ZfrtȈK6 $1$IfWD^` gdTkd=$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdXȈԈB- $1$IfWD^` gdTkd>$$IflTr +#& &&&&  #644 lagp2$$1$Ifa$gdX>`~6kd@$$IflTr +#& &&&&  #644 lagp2$$1$Ifa$gdX $$Ifa$gdX`zډ +,}~ƸƊƸviU'h654huCJKHPJaJnHo(tHh654hOCJKHaJ&h654hu5CJPJaJnHo(tH'h654hO.CJKHPJaJnHo(tH2h654hX5CJOJPJQJ^JaJnHo(tHh654hX5CJaJo($h654hXCJKHPJaJnHtHh654hXCJKHh654hXCJKHaJh654hXCJKHaJo(ډ +$$1$Ifa$gdX $$Ifa$gdX $1$IfWD^` gdT+,P;// $$Ifa$gdX $1$IfWD^` gdTkd4A$$IflXr +#& &&&&  #644 lagp2B- $1$IfWD^` gdTkdGB$$IflXr +#& &&&&  #644 lagp2$$1$Ifa$gdX%@ABDNʰzdL9%h654hm5CJOJQJ\]aJ/h654hm56OJPJQJ\]nHo(tH+h654hmCJOJPJQJaJnHo(tHh654hXCJKHh654hXCJKHaJo(h654hXCJKHaJh654hX5CJKHaJo(2h654hX5CJOJPJQJ^JaJnHo(tHh654hX5CJaJo($h654hXCJKHPJaJnHtH'h654hXCJKHPJaJnHo(tH)@A6kd>C$$IflXr +#& &&&&  #644 lagp2$$1$Ifa$gdX $$Ifa$gdXABDUV$%WXZd$If^Z`gddgdsW%<TPL HD@<e C^"7TPL HD@<e C^ $da$gd/e T^NORSTUVWËƋًۋϴ行}s}j`j`jVjF6h654hOCJPJnHo(tHh654h*WCJPJnHo(tHh654h*WCJo(h654h/eCJo(h654h/eCJh654h/eCJjh654h/eCJU(h654hm56CJOJQJ\]aJ%h654hm5CJOJQJ\]aJ4h654h)G5CJOJPJQJ\]aJnHo(tH1h654hm5CJOJPJQJ\]aJnHtH-h654hm5CJOJQJ\]aJnHtH"$%&\]`lu~Č23VWƼƳճգvvճvgvh654h4jCJPJnHtHh654h4jCJPJnHo(tHh654h4jCJh654h4jCJo(h654htCJo(h654htCJPJnHo(tHh654h/eCJh654h/eCJjh654h/eCJUh654h/eCJo(h654h/eCJPJnHo(tHh654hu"CJPJnHo(tHWXYpzϷz\I/'h654hRv5B*CJOJQJo(ph3h654hRv5B*CJOJPJQJnHo(phtH$h654hRv5B*CJOJQJph:h654hRv5B*CJOJPJQJ\aJnHo(phtH:h654hm5B*CJOJPJQJ\aJnHo(phtH=h654hqk5;B*CJOJPJQJ\aJnHo(phtH.h654hm5;B*CJOJQJ\aJph+h654hm5B*CJOJQJ\aJph4h654hmB*CJOJPJQJaJnHo(phtH ͍ύЍ֍ۍ !23<?ξξΜygUCΜ΋U# *h654hsWCJPJaJnHtH#h654hsWCJPJaJnHo(tH#h654hvCJPJaJnHo(tH#h654hsW5CJPJaJnHtH h654hsWCJPJaJnHtH *h654hsWCJaJ+h654hsW>*CJOJPJQJaJnHtHh654hsW>*CJOJQJaJh654hsWCJaJh654hsW5CJaJ3h654hm5B*CJOJPJQJnHo(phtH͍΍ύЍQ=Zd$If^Z`gdpkdQD$$Ifl\r#+vvv$4 a%$!d$Ifa$gd%$!d$4$Ifa$gd%$!d$Ifa$gdЍۍzfWHH$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdD$$Ifl\r#+vvv$4 a%$!d$Ifa$gdzk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdME$$Ifl\r#+vvv$4 a zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdE$$Ifl\r#+vvv$4 a !"zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdIF$$Ifl\r#+vvv$4 a"#12>JzkSS$d$&dIfPa$gd$d$Ifa$gdZd$If^Z`gdpkdF$$Ifl\r#+vvv$4 a?@ACIMNP]^emqrtӎَ܎ގߎ $%@BHSWYhijklmnqtvwzh654hsWCJaJo(#h654hvCJPJaJnHo(tH#h654hsWCJPJaJnHo(tHh654hsW5CJaJ h654hsWCJPJaJnHtHh654hsWCJaJBJKLMNOzk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdEG$$Ifl\r#+vvv$4 aOP]^fnzk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdG$$Ifl\r#+vvv$4 anopqrszk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdAH$$Ifl\r#+vvv$4 astzk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdH$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd=I$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdI$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd9J$$Ifl\r#+vvv$4 aюҎێzkXX$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdJ$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd5K$$Ifl\r#+vvv$4 a !zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdK$$Ifl\r#+vvv$4 a!"#$%&zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd1L$$Ifl\r#+vvv$4 a&'?@JTzk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdL$$Ifl\r#+vvv$4 aTUVWXYzk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd-M$$Ifl\r#+vvv$4 aYZhjs|zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdM$$Ifl\r#+vvv$4 a|}~zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd)N$$Ifl\r#+vvv$4 az}ǏȏɏʏϏՏ׏ۏ܏䵤~l`h654hsW5CJaJ# *h654hkCJPJaJnHtH& *h654hkCJPJaJnHo(tH#h654hkCJPJaJnHo(tH h654hkCJPJaJnHtHh654hkCJaJ#h654hsWCJPJaJnHo(tH#h654h*CJPJaJnHo(tHh654hsWCJaJ h654hsWCJPJaJnHtH%zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdN$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd%O$$Ifl\r#+vvv$4 aɏʏЏ֏zkSS$d$&dIfPa$gd{Xs$d$Ifa$gdZd$If^Z`gdpkdO$$Ifl\r#+vvv$4 a֏׏؏ُڏۏzk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd!P$$Ifl\r#+vvv$4 aۏ܏zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdP$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdQ$$Ifl\r#+vvv$4 a#,zkSS$d$&dIfPa$gd$d$Ifa$gdZd$If^Z`gdpkdQ$$Ifl\r#+vvv$4 a!+/02FGOW^rsǐʐϐՐސ !+3457Dwh654hx5CJ)h654hRv5CJPJ\aJnHo(tH#h654hsW5CJPJaJnHtHh654hsW5CJaJ *h654hsWCJaJ#h654hsWCJPJaJnHo(tH#h654hvCJPJaJnHo(tH h654hsWCJPJaJnHtHh654hsWCJaJ+,-./01zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdR$$Ifl\r#+vvv$4 a12FHPXzkSS$d$&dIfPa$gd$d$Ifa$gdZd$If^Z`gdpkdR$$Ifl\r#+vvv$4 aXYZ[\]zk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdS$$Ifl\r#+vvv$4 a]^zkVG$d$Ifa$gd$nd$4$If]na$gd$d$Ifa$gdZd$If^Z`gdpkdS$$Ifl\r#+vvv$4 a|m^^$d$Ifa$gd$d$Ifa$gdd$IfVDG^gdsWpkdT$$Ifl\r#+vvv$4 aɐʐА֐|mUU$d$&dIfPa$gd$d$Ifa$gdd$IfVDG^gdsWpkdT$$Ifl\r#+vvv$4 a֐אِؐڐېzk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdU$$Ifl\r#+vvv$4 aېܐݐސzkSS$d$&dIfPa$gd$d$Ifa$gdZd$If^Z`gdpkdU$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd V$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdV$$Ifl\r#+vvv$4 a "+4zkSS#$d$&dIfPa$gd$d$Ifa$gdZd$If^Z`gdpkdW$$Ifl\r#+vvv$4 a4567fgijuufL%$!d$4$Ifa$gdoK$d$Ifa$gd d$IfgdgdsWdgdRvpkdW$$Ifl\r#+vvv$4 aDefijƑˑ̑ӑԑܑ֑ߑ 9mXXLh654hsWCJaJo((h654hsWCJOJPJQJaJnHtH+h654hsWCJOJPJQJaJnHo(tH#h654hsW5CJPJaJnHtHh654hsW5CJaJh654hsWCJOJQJaJh654hsW>*CJOJQJaJh654hsWCJaJ h654hsWCJPJaJnHtH"h654hRv5CJPJnHo(tH"h654hx5CJPJnHo(tHuthY$d$Ifa$gd d$IfgdpkdX$$If\r+BY#$4 a%$!d$4$Ifa$gdoKs^^%$!d$4$Ifa$gd$d$Ifa$gd d$IfgdpkdX$$If\r+BY#$4 axiTT%$!d$4$Ifa$gd$d$Ifa$gd$d$IfWD^`$gdpkdY$$If\r+BY#$4 axiTT%$!d$4$Ifa$gd$d$Ifa$gd$d$IfWD^`$gdpkdY$$If\r+BY#$4 aˑ̑ԑܑzkMM%$!d$&d4$IfPa$gd$d$Ifa$gdZd$If^Z`gdpkdZ$$If\r+BY#$4 aܑݑޑߑzkVV%$!d$4$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdZ$$If\r+BY#$4 a zkVV%$!d$4$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd+[$$If\r+BY#$4 a OPV[zkVV%$!d$4$Ifa$gd$d$Ifa$gdd$If^`gdpkd[$$If\r+BY#$4 a9OPU[^opu}ђ)456:;=>~ҽ謚ҽrҽfh654hsW5CJaJ1h654hsWh^BCJOJPJQJaJnHo(tHh654hsWCJOJQJaJ#h654hsWCJPJaJnHo(tH h654hsWCJPJaJnHtH(h654hsWCJOJPJQJaJnHtH+h654hsWCJOJPJQJaJnHo(tHh654hsWCJaJh654hsWCJaJo(%[\xiTTT%$!d$4$Ifa$gd$d$Ifa$gd4d$IfWDt^4`gdpkdC\$$If\r+BY#$4 a56;=vgRR%$!d$4$Ifa$gd$d$Ifa$gdO[d$IfVDGWD^O`[gdsWpkd\$$If\r+BY#$4 a=>~qbbF%$!d$&dIfPa$gd$d$Ifa$gdJ:d$IfVD7WD^J`:gdsWukd[]$$If\r+BY#$4 agfT@1$d$Ifa$gdZd$If^Z`gdpkd]$$If\r+BY#$4 a%$!d$&dIfPa$gd%$!d$&d4$IfPa$gdԓՓޓycT8%$!d$&dIfPa$gd$d$Ifa$gd:d$IfWD^`:gdpkd}^$$If\r+BY#$4 a%$!d$4$Ifa$gdÓǓԓՓݓ$')*VWY[syz|”ɳɏɳɏɏɳɳɏɳh654hsW5CJOJQJaJh654hsWCJOJQJaJ(h654hsWCJOJPJQJaJnHtH+h654hsWCJOJPJQJaJnHo(tHh654hsWCJaJ#h654hsW5CJPJaJnHtHh654hsW5CJaJh654hsW5CJaJo(,ޓߓT@1$d$Ifa$gdZd$If^Z`gdpkd _$$If\r+BY#$4 a%$!d$&dIfPa$gd%$!d$&d4$IfPa$gdyeV8%$!d$&d4$IfPa$gd$d$Ifa$gdZd$If^Z`gdpkd_$$If\r+BY#$4 a%$!d$4$Ifa$gd$%&'()p\M88%$!d$4$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkd!`$$If\r+BY#$4 a%$!d$&d4$IfPa$gd)*VWX}E1Zd$If^Z`gd7kd3a$$Ifr#$$4 a%!d$Ifgdpkd`$$If\r+BY#$4 aXYZ[\rszjXnd$IfWD2`ngdpkda$$If\r+BY#$4 a%$!d$4$Ifa$gd$d$Ifa$gd|mOO%$!d$&d4$IfPa$gd$d$Ifa$gdnd$IfWD2`ngdpkd b$$If\r+BY#$4 azkVV%$!d$4$Ifa$gd$d$Ifa$gdZd$If^Z`gdpkdb$$If\r+BY#$4 azkMM%$!d$&d4$IfPa$gd$d$Ifa$gdZd$If^Z`gdpkd#c$$If\r+BY#$4 a”ÔiA-Zd0$If^Z`gdV(<TPL HD@<e C^gdim%<TPL HD@<e C^pkdc$$If\r+BY#$4 a”ÔД &ҸiSi;)#h654him>*CJPJaJnHtH.h654him>*CJOJPJQJaJnHo(tH+h654him>*CJOJPJQJaJnHtH+h654him>*CJOJPJQJaJnHtHh654him>*CJOJQJaJh654himCJaJ:h654him5B*CJOJPJQJ\aJnHo(phtH3h654him5B*CJOJPJQJnHo(phtH$h654him5B*CJOJQJph3h654hg5B*CJOJPJQJnHo(phtHD0Zd0$If^Z`gdVykd;d$$Ifl\A+f," 664 lags&%$!d0$Ifa$gdV%$!xd0$IfUD2]xa$gdV%$!d0$Ifa$gdV !"#$S?Zd0$If^Z`gdVykdd$$Ifl\A+f," 664 lags&$d0$Ifa$gdV$xd0$IfUD2]xa$gdV$d0$Ifa$gdV$%&9:;<wcT$d0$Ifa$gdVZd0$If^Z`gdVykde$$Ifl\A+f," 664 lags&$d0$Ifa$gdV&9OPQSVvwߕ -/06?^_fp–ÖŖ̖Ֆߖ256=Gqrwėʸʸʸʸʸʸʸʸʸʸʸ&h654himhCJPJaJnHtH#h654himCJPJaJnHo(tH h654himCJPJaJnHtHh654himCJaJo(h654himCJaJh654him5CJ\aJ@<=PQSWteVV$d0$Ifa$gdV$d0$Ifa$gdVld0$IfVD-^lgdVykd!f$$Ifl\A+f," 664 lags&WXvwteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdf$$Ifl\A+f," 664 lags&teVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdeg$$Ifl\A+f," 664 lags&ߕteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdh$$Ifl\A+f," 664 lags&teVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdh$$Ifl\A+f," 664 lags&/07>teVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdKi$$Ifl\A+f," 664 lags&>?^_goteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdi$$Ifl\A+f," 664 lags&opteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdj$$Ifl\A+f," 664 lags&–ĖteMM$d0$&dIfPa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykd1k$$Ifl\A+f," 664 lags&ĖŖƖǖȖɖrcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdk$$Ifl\A+f," 664 lags&ɖʖ˖̖֖rcKK$d0$&dIfPa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdul$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdm$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdm$$Ifl\A+f," 664 lags&teVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykd[n$$Ifl\A+f," 664 lags&346>FtteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdn$$Ifl\A+f," 664 lags&FGqrx~teVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdo$$Ifl\A+f," 664 lags&~teVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdAp$$Ifl\A+f," 664 lags&ؗٗܗޗteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdp$$Ifl\A+f," 664 lags&ėؗٗۗܗݗ!89@JOQWZ[_`ad͘ !"'()9<EHIŨŨh654him5CJ\aJh654himhCJaJo(h654himCJaJ h654himCJPJaJnHtHh654himCJaJo(#h654himCJPJaJnHo(tHBޗߗteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdq$$Ifl\A+f," 664 lags& teVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykd'r$$Ifl\A+f," 664 lags& !89AIteMM$d0$&dIfPa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdr$$Ifl\A+f," 664 lags&IJKLMNrcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdks$$Ifl\A+f," 664 lags&NOPQ[ezk\\$d0$Ifa$gdV$d0$Ifa$gdV d0$IfgdVykdt$$Ifl\A+f," 664 lags&efteMM$d0$&dIfPa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdt$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdQu$$Ifl\A+f," 664 lags&rcKK$d0$&dIfPa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdu$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdv$$Ifl\A+f," 664 lags&͘ΘϘИrcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd7w$$Ifl\A+f," 664 lags&ИјteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdw$$Ifl\A+f," 664 lags&!"(*teVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykd{x$$Ifl\A+f," 664 lags&*+FGIMteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdy$$Ifl\A+f," 664 lags&MNZ[agteVV$d0$Ifa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdy$$Ifl\A+f," 664 lags&IN[`rst{™ę",1WXamnorʚh654himCJ\aJo(h654him5CJ\aJh654himCJaJo(#h654himCJPJaJnHo(tHh654himCJaJ h654himCJPJaJnHtH=ghst|teMM$d0$&dIfPa$gdV$d0$Ifa$gdVd0$IfVDG^gdVykdaz$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd{$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd{$$Ifl\A+f," 664 lags&™ÙrcTT$d0$Ifa$gdV$d0$Ifa$gdVZ4d0$If^Z`4gdVykdG|$$Ifl\A+f," 664 lags&ÙęrcKK$d0$&dIfPa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd|$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd}$$Ifl\A+f," 664 lags&rcKK$d0$&dIfPa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd-~$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd~$$Ifl\A+f," 664 lags&#+rcKK$d0$&dIfPa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdq$$Ifl\A+f," 664 lags&+,-./0rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lags&01WXblrcKK$d0$&dIfPa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lags&lmnopqrcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykdW$$Ifl\A+f," 664 lags&qrrcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lags&rcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lag4s&ɚrcTT$d0$Ifa$gdV$d0$Ifa$gdVZd0$If^Z`gdVykd=$$Ifl\A+f," 664 lag4s&ɚʚrcKK$d0$&dIfPa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd߃$$Ifl\A+f," 664 lag4s&ʚ$%9:TUcdefhivwƛǛԛ՛)*+,./01EFh654h~CJaJo(h654h~5CJ\aJo( h654h~CJPJaJnHtHh654h~CJh654h~CJaJh654h~5CJ\aJ=rcTT$d0$Ifa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lag4s&$%/9rcTT$d0$Ifa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd#$$Ifl\A+f," 664 lag4s&9:TU\crcKK$d0$&dIfPa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykdŅ$$Ifl\A+f," 664 lag4s&cdefghrcTT$d0$Ifa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykdg$$Ifl\A+f," 664 lag4s&hivwrcKK$d0$&dIfPa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd $$Ifl\A+f," 664 lag4s&rcTT$d0$Ifa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lag4s&rcTT$d0$Ifa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykdM$$Ifl\A+f," 664 lag4s&ƛǛ͛ԛrcTT$d0$Ifa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lag4s&ԛ՛rcTT$d0$Ifa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lag4s& rcKK$d0$&dIfPa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd3$$Ifl\A+f," 664 lag4s&rcTT$d0$Ifa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykdՊ$$Ifl\A+f," 664 lag4s&!)zkSS$d0$&dIfPa$gd1$d0$Ifa$gdV d0$IfgdVykdw$$Ifl\A+f," 664 lag4s&)*+,-.zk\\$d0$Ifa$gd1$d0$Ifa$gdV d0$IfgdVykd$$Ifl\A+f," 664 lag4s&./01;ErcKK$d0$&dIfPa$gd1$d0$Ifa$gdVZd0$If^Z`gdVykd$$Ifl\A+f," 664 lag4s&EFG%&QRto__d^`gds"gd1Ydd^`gd1Ydykd]$$Ifl\A+f," 664 lag4s& FGWYfмpbF7!+h654h0 CJOJPJQJaJnHo(tHh654h1Yd5CJ\aJo(6h654hHz5CJKHOJPJQJ\^JaJnHtHh654h1Yd5CJ\aJ-h654h0 5@CJPJ\aJnHo(tH2h654hm5@CJOJPJQJ\aJnHtH5h654h;[5@CJOJPJQJ\aJnHo(tH&h654h0 5@CJOJQJ\aJ&h654h 5@CJOJQJ\aJ5h654hg5@CJOJPJQJ\aJnHo(tH $%$%&*+:Iϴo`K=.h654hHz5CJ\aJo(h654hHz5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654h1Yd5CJ\aJo((h654h1YdCJOJPJQJaJnHtH-h654hhB*CJOJQJaJnHphtH0h654hhB*CJOJQJaJnHo(phtH4h654hhB*CJOJPJQJaJnHo(phtH1h654h1YdB*CJOJPJQJaJnHphtH-h654h1YdB*CJOJQJaJnHphtHIJR+/9;]_ğşϟП)*+UY\]BCݡޡߡѼѼѪŪżѼŪѼѼѼżż#h654hCJPJaJnHo(tHh654haJh654hCJaJo(h654hCJaJh654hHz5CJ\aJ)h654h7m 5CJPJ\aJnHo(tH?R:;OyJkd$$If07f"/ | 4 a$IfVDWD~^`gd$IfVDWD~^`gd$JdVD_^Ja$gdП*?Jkdَ$$If07f"/ | 4 a$IfVDWD~^`gd$IfVDWD~^`gdJkdl$$If07f"/ | 4 a*+=\]q?Jkd$$If07f"/ | 4 a$IfVDWD~^`gd$IfVDWD~^`gdJkdF$$If07f"/ | 4 a?Jkd$$If07f"/ | 4 a$IfVDWD~^`gd$IfVDWD~^`gdJkd $$If07f"/ | 4 aޡ?Jkdg$$If07f"/ | 4 a$IfVDWD~^`gd$IfVDWD~^`gdJkd$$If07f"/ | 4 aޡߡ01x$d^a$gd$JdVD_^Ja$gd$7$8$H$^a$gd $d1$a$gdJkdԑ$$If07f"/ | 4 a ߡCD`hâĢ0Iz-.89XY)*yͻzsgh654hhO-CJ h654hh654hCJH*h654hCJo(h654hCJh654hCJPJ ^Jh654hCJaJh654hCJaJo(#h654hCJPJaJnHo(tH&h654h6CJPJaJnHo(tHh654h6CJaJo( h654hCJPJaJnHtH(*{|CSkd$$Ifl0p#Ja t 644 la1SkdA$$Ifl0p#Ja t 644 la1Sd$If^`Sgdyz{|ا٧ڧۧ;<=>CD^_}~0134ȩٿٳٛ h654hCJPJaJnHtHh654hCJaJo(h654h5CJo(h654hCJH*o(h654hCJPJnHo(tHh654hCJo(h654hCJ h654hh654hhO-CJh654hCJH*6ڧۧ&=CSkdm$$Ifl0p#Ja t 644 la1Skd $$Ifl0p#Ja t 644 la1Sd$If^`Sgd=>R-Skd5$$Ifl0p#Ja t 644 la1Pd$IfWD^`PgdSd$If^`SgdSkdѓ$$Ifl0p#Ja t 644 la1è3CSkd$$Ifl0p#Ja t 644 la1Skd$$Ifl0p#Ja t 644 la1Sd$If^`Sgd34G-Skdŕ$$Ifl0p#Ja t 644 la1Sd$IfVD^`SgdSd$If^`SgdSkda$$Ifl0p#Ja t 644 la14wFgh;<!$ & F d1$7$8$H$^`a$gds$d7$8$H$^a$gddgd6dVDWD^6`gd~4$dVDWD^4`$gd$YVDe^Ya$gdȩ˩3457vwxDFGHIӳӏo^L#h654h~CJPJaJnHo(tH h654h~CJPJaJnHtHh654hET8CJPJnHo(tHh654h~CJH*PJnHtH"h654h~CJH*PJnHo(tH"h654hCJH*PJnHo(tHh654hCJPJnHo(tHh654hCJH*PJnHtHh654hCJ h654hCJPJaJnHtH#h654hCJPJaJnHo(tHë߫59ghoxǬȬxyڭۭ;<%QR$%/ZeLM';<mnow{ʹ״״ŴŴ h654hCJPJaJnHtH#h654hCJPJaJnHo(tHh654hCJaJo(h654hCJaJh654hCJh654h~CJGkl Ըո$d$Ifa$gdsVd$IfVD^Vgds$d^a$gds$d^a$gdsgdTd^`gds" $7$8$H$a$gd$7$8$H$^a$gdʹδԴմشOPjkuvabطٷDEOP]`x~Ըո޸߸⪛m\m h654hsCJPJaJnHtH#h654hsCJPJaJnHo(tHh654hTPJnHo(tHh654hT5CJ\aJh654hT5CJ\aJo(5h654h1Yd5CJKHOJPJQJ\aJnHo(tHh654hCJaJ#h654hCJPJaJnHo(tH h654hCJPJaJnHtHh654hCJaJo($Ge*+,GaUVXYsvwĻǻһ JK¼üҺҮҮҮh654h8CJaJh654h8>*CJaJ#h654h8>*CJPJaJnHtHh654hsCJ]aJh654hs>*CJaJh654hsCJaJo(h654hsCJaJ#h654hsCJPJaJnHo(tH h654hsCJPJaJnHtH1G2$Vd$IfVD^Va$gdsLkd$$If0p#/ | 4 aS d$IfgdsVd$IfVD^VgdsLkd)$$If0p#/ | 4 aSTUVWXuvGLkd$$If0p#/ | 4 aSVd$IfVD^VgdsLkd $$Ifq0p#/ | 4 aS d$Ifgdsvƻ8Lkdv$$If0p#/ | 4 aS d$IfgdsVd$IfVD^VgdsLkd$$If0p#/ | 4 aS$d$Ifa$gdsƻǻ KLijq\\G$\d$VDQ^\`a$gds$\#d$VDQ^\`#a$gds$dWD,`a$gdx$d^a$gdsLkd$$If0p#/ | 4 aS$d$Ifa$gdsVd$IfVD^Vgdsj¼$@A$d$$&dIfPa$gdB^&d$$If^`&gdB^$\d$VDQ^\`a$gd8$\#d$VDQ^\`#a$gd8$\d$VDQ^\`a$gds$\#d$VDQ^\`#a$gdsABOPQW$d$$&dIfPa$gdB^OWXýĽ˽νϽѽҽӽԽսֽ׽ڽ۽޽߽ ͻͻ{{{{{ͻ&h654h8hewCJPJaJnHtH#h654h8CJPJaJnHo(tHh654h8h CJaJh654h8CJ]aJ#h654h8CJPJ]aJnHtHh654h8CJaJh654h8>*CJaJh654h8CJaJ h654h8CJPJaJnHtH0WXY,&d$$If^`&gdB^kdj$$If֞  yU"5&Nnnnn0p#4 aSYaiqy$d$$Ifa$gdB^oԦ$d$$Ifa$gdB^,&d$$If^`&gdB^kdX$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^oԦ$d$$Ifa$gdB^,&d$$If^`&gdB^kd@$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^oԦ$d$$Ifa$gdB^,&d$$If^`&gdB^oԦkd.$$If֞  yU"5&Nnnnn0p#4 aSĽ̽ӽս߽$d$$Ifa$gdB^߽,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS $d$$&dIfPa$gdB^%&(-.68>?FJKMNOPSTWXYZ[^_cdeklt|ȽȽȆȽh654h8hewCJaJ#h654h8CJPJ]aJnHtHh654h8CJaJh654h8CJ]aJh654h8CJaJ h654h8CJPJaJnHtH&h654h8hewCJPJaJnHtH#h654h8CJPJaJnHo(tH4,&d$$If^`&gdB^kd$$If֞  yU"5&Nnnnn0p#4 aS !"#$%$d$$Ifa$gdB^%&-,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS-7?GOYc$d$$&dIfPa$gdB^cde,&d$$If^`&gdB^kd$$If֞  yU"5&Nnnnn0p#4 aSefghijk$d$$Ifa$gdB^kl|,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS|$d$$Ifa$gdB^$d$$&dIfPa$gdB^,&d$$If^`&gdB^kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^,ad$$If^`agdB^kdԢ$$If֞  yU"5&Nnnnn0p#4 aSǾȾɾʾξϾоѾ  !"AEFLMNRTUhlͿ͢ͿͿ͢ͿͿͿͿ͢h654h8CJaJh654h8CJ]aJh654h8CJaJo(h654h8CJaJ#h654h8CJPJaJnHo(tHh654h8hewCJaJ h654h8CJPJaJnHtH&h654h8CJPJ]aJnHo(tHh654h8CJ]aJo(.Ⱦ$d$$Ifa$gdB^Ⱦɾʾ,ad$$If^`agdB^kdȣ$$If֞  yU"5&Nnnnn0p#4 aSʾ˾̾;ξϾо$d$$Ifa$gdB^оѾ,ad$$If^`agdB^kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^,ad$$If^`agdB^kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^ ,ad$$If^`agdB^kd$$If֞  yU"5&Nnnnn0p#4 aS $d$$Ifa$gdB^,ad$$If^`agdB^kd$$If֞  yU"5&Nnnnn0p#4 aS !$d$$Ifa$gdB^!"A,ad$$If^`agdB^kd$$If֞  yU"5&Nnnnn0p#4 aSABCDEFL$d$$&dIfPa$gdB^$d$$Ifa$gdB^LMN,&d$$If^`&gdB^kd$$If֞  yU"5&Nnnnn0p#4 aSNOPQRST$d$$Ifa$gdB^TUh,ad$$If^`agdB^kdt$$If֞  yU"5&Nnnnn0p#4 aShijklmu$d$$&dIfPa$gdB^$d$$Ifa$gdB^lmpqrtuvw}~PWX\]^_pyz۾wwۧkYKۧYh654h8h CJaJ#h654h8CJPJ]aJnHtHh654h8>*CJaJh654h8>*CJaJ#h654h8>*CJPJaJnHtH#h654h8CJPJaJnHo(tHh654h8CJaJh654h8CJ]aJh654h8CJaJ#h654h8CJPJaJnHo(tH h654h8CJPJaJnHtH&h654h8hewCJPJaJnHtHuvw,&d$$If^`&gdB^kdh$$If֞  yU"5&Nnnnn0p#4 aSwxyz{|}$d$$Ifa$gdB^oԦ$d$$Ifa$gdB^}~,! $d$a$gd8kdj$$If֞  yU"5&Nnnnn0p#4 aS˿̿$d$$&dIfPa$gdB^&d$$If^`&gdB^$\d$VDQ^\`a$gd8$\.d$VDQ^\`.a$gd8,&d$$If^`&gdB^kdf$$If֞  yU"5&Nnnnn0p#4 aS'/7?G$d$$Ifa$gdB^oԦ$d$$Ifa$gdB^GHI,&d$$If^`&gdB^kdT$$If֞  yU"5&Nnnnn0p#4 aSIJKLMNO$d$$Ifa$gdB^oԦ$d$$Ifa$gdB^OPX,&d$$If^`&gdB^kd<$$If֞  yU"5&Nnnnn0p#4 aSXYZ[\]^$d$$Ifa$gdB^oԦ$d$$Ifa$gdB^^_p,&d$$If^`&gdB^kd*$$If֞  yU"5&Nnnnn0p#4 aSpz$d$$Ifa$gdB^z !")189=@DGTUVWYZ[^_`ahtовввв~вФ&h654h8hrCJPJaJnHtH#h654h8CJPJaJnHo(tHh654h8CJ]aJo(h654h8CJ]aJ#h654h8CJPJ]aJnHtHh654h8CJaJ&h654h8hewCJPJaJnHtH h654h8CJPJaJnHtH,,hd$$IfVD&WD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$&dIfPa$gdB^,&d$$If^`&gdB^kd $$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS  $d$$&dIfPa$gdB^ !",&d$$If^`&gdB^kd$$If֞  yU"5&Nnnnn0p#4 aS"#$%&'($d$$Ifa$gdB^()9,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS9AHNVW_$d$$Ifa$gdB^$d$$&dIfPa$gdB^_`a,&d$$If^`&gdB^kdܵ$$If֞  yU"5&Nnnnn0p#4 aSabcdefg$d$$Ifa$gdB^gh{,hd$$IfVDWD^`hgdB^kdж$$If֞  yU"5&Nnnnn0p#4 aStz{ '+͹͜͹͜͹ͧ͐͹͜͹͹͹x͜xh654h8CJ]aJh654h8CJaJo( *h654h8CJaJh654h8CJaJ#h654h8CJPJaJnHo(tH&h654h8hewCJPJaJnHtH h654h8CJPJaJnHtHh654h8CJ]aJo(&h654h8CJPJ]aJnHo(tH/{|}~$d$$Ifa$gdB^,hd$$IfVDWD^`hgdB^kdķ$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^oVd$d$$Ifa$gdB^,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^,hd$$IfVDWD^`hgdB^kd$$If֞  yU"5&Nnnnn0p#4 aS $d$$&dIfPa$gdB^$d$$Ifa$gdB^ ,hd$$IfVDWD^`hgdB^kd|$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdB^',hd$$IfVDWD^`hgdB^kdp$$If֞  yU"5&Nnnnn0p#4 aS'()*+,4$d$$&dIfPa$gdB^$d$$Ifa$gdB^+,356 !/1YhQRпxg[J h654himCJPJaJnHtHh654himCJ]aJ h654himCJPJaJnHtHh654hs>*CJaJ#h654hs>*CJPJaJnHtHh654hsCJaJo(#h654hsCJPJaJnHo(tHh654hsCJaJ h654hsCJPJaJnHtHh654h8CJaJ h654h8CJPJaJnHtH&h654h8hewCJPJaJnHtH456,'gdskdd$$If֞  yU"5&Nnnnn0p#4 aS6RSrsuu$d$$&dIfPa$gdV&d$$If^`&gdVgdim$\d$VDQ^\`a$gds$\#d$VDQ^\`#a$gds WDh`gds$dWDh^`a$gds$d^a$gds8ABklr %),.045678<ABƴ䨴ب䨴䴨h654himCJaJo(#h654himCJPJaJnHo(tH#h654himCJPJ]aJnHtHh654himCJ]aJ h654himCJPJaJnHtHh654himCJaJB9:@$d$$&dIfPa$gdV@ABJ?+$d$$Ifa$gdV&d$$If^`&gdVkdf$$Ifֈ sok $ Hnt0"4 aSJRZbjk0kd`$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdVklmnopq$d$$Ifa$gdV&d$$If^`&gdVqr?+$d$$Ifa$gdV&d$$If^`&gdVkdT$$Ifֈ sok $ Hnt0"4 aS0kdH$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdV$d$$Ifa$gdV&d$$If^`&gdV?+$d$$Ifa$gdV&d$$If^`&gdVkdB$$Ifֈ sok $ Hnt0"4 aS$d$$&dIfPa$gdV$d$$Ifa$gdV?+$d$$Ifa$gdV&d$$If^`&gdVkd<$$Ifֈ sok $ Hnt0"4 aS0kd6$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdV $d$$&dIfPa$gdV$d$$Ifa$gdV&d$$If^`&gdV ?+$d$$Ifa$gdV&d$$If^`&gdVkd0$$Ifֈ sok $ Hnt0"4 aS 0kd*$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdV%-5<CK$d$$Ifa$gdV&d$$If^`&gdVBCDFGJLMS_`juvw{}˹ˤp\pQh654himCJaJ&h654himh5CJPJaJnHtH&h654himh CJPJaJnHtHh654himh CJ]aJ h654himCJPJaJnHtH)h654himh^TCJPJ]aJnHtH#h654himCJPJ]aJnHtHh654himCJ]aJh654himCJaJo(#h654himCJPJaJnHo(tHh654himCJaJKLMN?+$d$$Ifa$gdV&d$$If^`&gdVkd$$$Ifֈ sok $ Hnt0"4 aSNOPQRS0kd$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdVSwxyz{$d$$&dIfPa$gdV$d$$Ifa$gdV&d$$If^`&gdV?+$d$$Ifa$gdV&d$$If^`&gdVkd$$Ifֈ sok $ Hnt0"4 aS0kd$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdV$d$$&dIfPa$gdV$d$$Ifa$gdV&d$$If^`&gdV?4$\#d$VDQ^\`#a$gdim $d$a$gdimkd$$Ifֈ sok $ Hnt0"4 aS()RSYhklruvz *,234Ѵ#h654himCJPJaJnHo(tHh654himCJaJo(#h654himCJPJ]aJnHtH h654himCJPJaJnHtHh654him>*CJaJ#h654him>*CJPJaJnHtH#h654himCJPJaJnHo(tHh654himCJaJ4 !'$d$$&dIfPa$gdV&d$$If^`&gdVgdim$\#d$VDQ^\`#a$gdim '()?+&d$$If^`&gdVkd"$$Ifֈ/ wQ$j Hnt0!4 aS)19AIQ$&d$$If^`&a$gdVQRSTU?+++&d$$If^`&gdVkd*$$Ifֈ/ wQ$j Hnt0!4 aSUVWXY+kd,$$Ifֈ/ wQ$j Hnt0!4 aS&d$$If^`&gdVYhrz$&d$$If^`&a$gdV&d$$If^`&gdV?+&d$$If^`&gdVkd.$$Ifֈ/ wQ$j Hnt0!4 aS$&d$$If^`&a$gdV?+&d$$If^`&gdVkd6$$Ifֈ/ wQ$j Hnt0!4 aS$&d$$&dIfP^`&a$gdV$&d$$If^`&a$gdV?+&d$$If^`&gdVkd>$$Ifֈ/ wQ$j Hnt0!4 aS$&d$$If^`&a$gdV?+&d$$If^`&gdVkdF$$Ifֈ/ wQ$j Hnt0!4 aS$&d$$&dIfP^`&a$gdV$&d$$If^`&a$gdV?+&d$$If^`&gdVkdN$$Ifֈ/ wQ$j Hnt0!4 aS$&d$$If^`&a$gdV ?+&d$$If^`&gdVkdV$$Ifֈ/ wQ$j Hnt0!4 aS #*2$&d$$If^`&a$gdV234?+&d$$If^`&gdVkd^$$Ifֈ/ wQ$j Hnt0!4 aS456789$&d$$If^`&a$gdV9:^?+&d$$If^`&gdVkdf$$Ifֈ/ wQ$j Hnt0!4 aS4:\]^cefjklmnprSV`ayn\n\nPn\n\P\nh654hsCJaJo(#h654hsCJPJaJnHo(tH h654hsCJPJaJnHtH#h654himCJPJaJnHo(tHh654himh5CJaJh654himh CJaJ)h654himh CJPJ]aJnHtHh654himCJaJo()h654himh^TCJPJ]aJnHtH#h654himCJPJ]aJnHtHh654himCJaJ^_`abj$&d$$&dIfP^`&a$gdV$&d$$If^`&a$gdVjkl?+&d$$If^`&gdVkdn$$Ifֈ/ wQ$j Hnt0!4 aSlmnopq$&d$$If^`&a$gdVqr?+&d$$If^`&gdVkdv$$Ifֈ/ wQ$j Hnt0!4 aS$&d$$&dIfP^`&a$gdV$&d$$If^`&a$gdV?:,$`VDh^`a$gdsgdskd~$$Ifֈ/ wQ$j Hnt0!4 aS}&d$$If^`&gds$`VDh^`a$gdsgds$\d$VDQ^\`a$gds$\#d$VDQ^\`#a$gds|`gds$d^a$gds$ & F da$gds VD^gds y{~|}䟓|||jXLXL|XLXh654hsCJaJo(#h654hsCJPJaJnHo(tH#h654hsCJPJ]aJnHtHh654hsCJaJh654hsCJ]aJh654hs>*CJaJ#h654hs>*CJPJaJnHtH(h654hsCJOJPJQJaJnHtH#h654hsCJPJaJnHo(tHh654hsCJaJo( h654hsCJPJaJnHtHh654hsCJaJ45BXtu{$d$$&dIfPa$gds{|}?+$d$$Ifa$gds&d$$If^`&gdskd$$IfֈB>:!% Hnt0"4 aS0kd$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gds$d$$Ifa$gds&d$$If^`&gds?3$$$d$$Ifa$gds d$$Ifgdskdt$$IfֈB>:!% Hnt0"4 aS!"#$%.0368E_klqrvwxyz{觹觹#h654hsCJPJ]aJnHtHh654hsCJ]aJ#h654hsCJPJaJnHo(tH h654hsCJPJaJnHtHh654hsCJaJh654hsCJaJo(;0kdh$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gds"(/7$d$$Ifa$gds&d$$If^`&gds78lr?+$d$$Ifa$gds&d$$If^`&gdskdb$$IfֈB>:!% Hnt0"4 aSrwy{0kd\$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gds$d$$Ifa$gds&d$$If^`&gds?+$d$$Ifa$gds&d$$If^`&gdskdV$$IfֈB>:!% Hnt0"4 aS)./4589>?@AGHNOȷȷȷȷȷȷȷ}q}}_Sh654hs>*CJaJ#h654hs>*CJPJaJnHtHh654hsCJaJo( h654hsCJPJaJnHtH#h654hsCJPJaJnHo(tHh654hsCJ]aJh654hsCJaJ h654hsCJPJaJnHtH#h654hsCJPJaJnHo(tH#h654hsCJPJ]aJnHtH&h654hsCJPJ]aJnHo(tH 0kdP$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gds)/579?$d$$&dIfPa$gds&d$$If^`&gds?@AB?+$d$$Ifa$gds&d$$If^`&gdskdJ$$IfֈB>:!% Hnt0"4 aSBCDEFG0kdR$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdsGH`abwx$d$&dIfPa$gdsd$If^`gds$d^a$gd'HdVD^^Hgds$\#dVDQ^\`#a$gds$>dVDaWD^`>a$gds`ab ./ƺlZFZFZFZF&h654hshewCJPJaJnHtH#h654hsCJPJaJnHo(tH&h654hsCJPJ]aJnHo(tH#h654hsCJPJ]aJnHtHh654hs>*CJaJ h654hsCJPJaJnHtHh654hsCJaJh654hsCJaJo(h654hsCJaJ h654hsCJPJaJnHtHh654hs>*CJPJaJo(h654hs>*CJaJo(?+$d$Ifa$gdsd$If^`gdskdT$$Ifֈ F % no0V"4 aS0kdH$$Ifֈ F % no0V"4 aS$d$Ifa$gds$d$Ifa$gdsd$If^`gds ?+$d$Ifa$gdsd$If^`gdskd6$$Ifֈ F % no0V"4 aS 0kd*$$Ifֈ F % no0V"4 aS$d$Ifa$gds.48<AG$d$Ifa$gd$d$Ifa$gd1d$If^`gds/013479<>AFGHz{|~ܿܿܿ#h654hsCJPJ]aJnHtHh654hsCJ]aJh654hsCJaJ#h654hCJPJaJnHo(tH h654hsCJPJaJnHtH#h654hsCJPJaJnHo(tH?GHz?'sd$IfVDWD^`sgdskd,$$Ifֈ F % no0V"4 aSz$d$$Ifa$gds?+$d$Ifa$gdsd$If^`gdskd:$$Ifֈ F % no0V"4 aS0kd4$$Ifֈ F % no0V"4 aS$d$Ifa$gds$d$&dIfPa$gdsd$If^`gds&'Z]no$+,23>?FGHeflmst}~ҋҋymmmmymmmmh654hsCJaJo(#h654hsCJPJ]aJnHtHh654hsCJ]aJh654hsCJaJo( h654hsCJPJaJnHtHh654hs>*CJaJ#h654hs>*CJPJaJnHtHh654hsCJaJ#h654hsCJPJaJnHo(tH h654hsCJPJaJnHtH)?*$\dVDQ^\`a$gdskd6$$Ifֈ F % no0V"4 aS'(mno$d$&dIfPa$gds&d$If^`&gds$`dVDh^`a$gdsdgds$\#dVDQ^\`#a$gds ?+$d$Ifa$gds&d$If^`&gdskd8$$Ifֈ FD!% nHHt0"4 aS0kd2$$Ifֈ FD!% nHHt0"4 aS$d$Ifa$gds$d$Ifa$gds&d$If^`&gds$?'sd$IfVDWD^`sgdskd&$$Ifֈ FD!% nHHt0"4 aS$,37?G$d$Ifa$gdsGHf?'sd$IfVDWD^`sgdskd$$Ifֈ FD!% nHHt0"4 aSfmtx~$d$Ifa$gds?'sd$IfVDWD^`sgdskd$$Ifֈ FD!% nHHt0"4 aS '*+./4589:;ABȷȷȷȷȷȷȷȷȷȷȷȷq#h654hsCJPJaJnHo(tHh654hsCJaJo( h654hsCJPJaJnHtHh654hsCJaJo(h654hsCJaJ h654hsCJPJaJnHtHh654hsCJaJo(#h654hsCJPJ]aJnHtHh654hsCJ]aJh654hsCJ]aJo(*$d$Ifa$gds?'sd$IfVDWD^`sgdskd$$Ifֈ FD!% nHHt0"4 aS $d$Ifa$gds '?'sd$IfVDWD^`sgdskd$$Ifֈ FD!% nHHt0"4 aS'+/359$d$&dIfPa$gds9:;?+JdVDWD^`Jgdskd$$Ifֈ FD!% nHHt0"4 aS;./0EFSi$d$&dIfPa$gds&d$If^`&gdsHdVD^^Hgds$HdVD^^Ha$gdsJdVDWD^`Jgds$>dVDaWD^`>a$gds /0 F_`nvw~䵡䵕ӕӕu䵕ӕӕӕ䵕ӕӕh654hsCJ]aJ&h654hshewCJPJaJnHtHh654hsCJaJo(&h654hsCJPJ]aJnHo(tH#h654hsCJPJ]aJnHtHh654hs>*CJaJ h654hsCJPJaJnHtHh654hsCJaJ h654hsCJPJaJnHtH.?+$d$Ifa$gds&d$If^`&gdskd $$Ifֈ F % no0V"4 aS0kd$$Ifֈ F % no0V"4 aS$d$Ifa$gds$d$Ifa$gds&d$If^`&gds?+$d$Ifa$gdsd$If^`gdskd$$Ifֈ F % no0V"4 aS0kd$$Ifֈ F % no0V"4 aS$d$Ifa$gds $d$Ifa$gdsd$If^`gdsF?'sd$IfVDWD^`sgdskd$$Ifֈ F % no0V"4 aSFMSVX_$d$Ifa$gds_`nw?+$d$Ifa$gdsd$If^`gdskd$$Ifֈ F % no0V"4 aSw0kd$$Ifֈ F % no0V"4 aS$d$Ifa$gds$d$&dIfPa$gdsd$If^`gds :;DGHIijlpvw{Ƶ}nn}Zn}ZJh654hs>*CJOJQJaJ'h654hs>*CJOJQJaJnHtHh654hsCJOJQJaJ(h654hsCJOJPJQJaJnHtHh654h'CJaJo(h654hsCJaJo(h654hsCJaJ h654hsCJPJaJnHtH#h654hsCJPJaJnHo(tHh654hsCJaJh654hsCJaJo( h654hsCJPJaJnHtH?:))6VDWD^`6gdsgdskd$$Ifֈ F % no0V"4 aSGHIjklwgSS%$!d$Ifa$gdsMkd$$If40#& 9!4 aSf4%$!d$Ifa$gds$d$IfWD^`$gds6VDWD^`6gds$d^a$gd'ww%$!d$Ifa$gds$d$IfWD^`$gds]kdi$$IfFu#&9!    4 aS||$d$Ifa$gds$d$IfWD^`$gds]kd$$IfFu#&9!    4 aS$d$Ifa$gds d$Ifgds]kdo$$IfFu#&9!    4 aS$d$Ifa$gds d$Ifgds]kd$$IfFu#&9!    4 aS ",GZz ѯ}i^h654h+c\CJaJ&h654h+c\5CJPJ\aJnHtHh654hT5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654hT5CJ\aJo(+h654hmCJOJPJQJaJnHo(tHh654hsCJaJo(h654hsCJaJ h654hsCJPJaJnHtH#h654hsCJPJaJnHo(tH$d$Ifa$gds d$Ifgds]kd{$$IfFu#&9!    4 aS$d$Ifa$gds d$Ifgds]kd$$IfFu#&9!    4 aS }}$d$&dIfPa$gds d$Ifgds]kd$$IfFu#&9!    4 aS$d$Ifa$gds d$Ifgds]kd$$IfFu#&9!    4 aS#-}}$d$&dIfPa$gds d$Ifgds]kd$$IfFu#&9!    4 aS-./qidgd+c\d^`gds"$d^a$gds$d^a$gds]kd($$IfFu#&9!    4 aS &123>Iy]kd$$IflF$&!    4 la1%$!d$Ifa$gd2Hd$If^H`gd2%&*013I]^_`mnop29>?inuwƻwwewwewwewwewewwew#h654h+c\CJPJaJnHo(tH h654h+c\CJPJaJnHtH#h654h+c\>*CJOJPJ QJaJ h654h+c\CJOJPJ QJaJh654h+c\>*CJOJQJaJh654h+c\CJaJ+h654h+c\>*CJOJPJQJaJnHtH(h654h+c\CJOJPJQJaJnHtHh654h+c\CJOJQJaJ'IJKS[~~$d$Ifa$gd2Hd$If^H`gd2]kd+$$IflF$&!    4 la1[\]^_xx'$ d$Ifa$gd2Hd$If^H`gd2]kd$$IflF$&!    4 la1_`mnoxx'$ d$Ifa$gd2Hd$If^H`gd2]kd%$$IflF$&!    4 la1op{{$d$Ifa$gd2d$IfWDd`gd2bkd$$IflF$&!    4 la1gN &pp$d$&dIfPa$gd2 & F=d$1$If^=`gds]kd#$$IflF$&!    4 la1$d$Ifa$gd2 d$Ifgd2]kd$$IflF$&!    4 la1$d$Ifa$gd2 d$Ifgd2]kd#$$IflF$&!    4 la12:>$d$Ifa$gd2 d$Ifgd2]kd$$IflF$&!    4 la1>?iou}}$d$&dIfPa$gd2 d$Ifgd2]kd#$$IflF$&!    4 la1uvwxy$d$Ifa$gd2 d$Ifgd2]kd$$IflF$&!    4 la1wy{ư~iTI:h654hCJOJQJaJh654hCJaJ)h654hT5CJPJ\aJnHo(tH)h654h5CJPJ\aJnHo(tHh654hT5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654hT5CJ\aJo(+h654hmCJOJPJQJaJnHo(tHh654h+c\CJaJo(#h654h+c\CJPJaJnHo(tHh654h+c\CJaJ h654h+c\CJPJaJnHtHyz{}}$d$&dIfPa$gd2 d$Ifgd2]kd# $$IflF$&!    4 la1wcOO%$!d$Ifa$gd2Hd$If^H`gd20d^`0gdd^`gds"dgd+c\]kd $$IflF$&!    4 la1$*+./HIRX^fhi{)2:HJ׽yymyyayȊyy *h654hCJaJh654hCJaJo( h654hCJPJaJnHtH#h654hCJPJaJnHo(tH h654hCJOJPJ QJaJh654h>*CJOJQJaJh654hCJaJh654hCJOJQJaJ'h654h>*CJOJQJaJnHtH(h654hCJOJPJQJaJnHtH&yy%$!d$Ifa$gd2Hd$If^H`gd2]kd# $$IflF$&!    4 la1~~$d$Ifa$gd2Hd$If^H`gd2]kd $$IflF$&!    4 la1xx'$ d$Ifa$gd2Hd$If^H`gd2]kd $$IflF$&!    4 la1$d$Ifa$gd2 d$Ifgd2]kd $$IflF$&!    4 la1 $$d$Ifa$gd2 d$Ifgd2]kd $$IflF$&!    4 la1$%HJR}}$d$&dIfPa$gd2 d$Ifgd2]kd $$IflF$&!    4 la1RSTUV$d$Ifa$gd2 d$Ifgd2]kd $$IflF$&!    4 la1VWX_f$d$Ifa$gd2 d$Ifgd2]kd$$IflF$&!    4 la1fghij$d$Ifa$gd2 d$Ifgd2]kd $$IflF$&!    4 la1jk{}}$d$&dIfPa$gd2 d$Ifgd2]kd$$IflF$&!    4 la1~~#$d$Ifa$gd2Hd$If^H`gd2]kd $$IflF$&!    4 la1pp$d$&dIfPa$gd2%!Hd$If^H`gd2]kd$$IflF$&!    4 la1KLrsvR#9TPL HD@<+{^$dVD,^a$gd$d^a$gd $da$gd]kd $$IflF$&!    4 la1JNX[\r^b﫜ydYEY&h654hi`q5CJPJ\aJnHtHh654hi`qCJaJ)h654h[5CJPJ\aJnHo(tHh654h[5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654h[5CJ\aJo(4h654hmB*CJOJPJQJaJnHo(phtHh654hCJaJ#h654hCJPJaJnHo(tHh654hCJaJo( h654hCJPJaJnHtHK]kd$$IflF$&!    4 la1%$!d$Ifa$gd2d$IfWD^`gd2dgdi`q d`gdi`qdgd[d^`gd}a&'@cjkmr456:<=ABCgnwxyz{ƻ|h654hi`qCJaJo(#h654hi`qCJPJaJnHo(tH h654hi`qCJPJaJnHtHh654hi`q>*CJOJQJaJh654hi`qCJaJ+h654hi`q>*CJOJPJQJaJnHtH(h654hi`qCJOJPJQJaJnHtHh654hi`qCJOJQJaJ0'/whh$d$Ifa$gd2]kd$$IflF$&!    4 la1%$!d$Ifa$gd2d$IfWD^`gd2/0123||#$d$Ifa$gd2d$IfWD^`gd2]kd$$IflF$&!    4 la134ckszz#$d$Ifa$gd2sd$IfVDWD^`sgdi`q]kd$$IflF$&!    4 la1stzz#$d$Ifa$gd2sd$IfVDWD^`sgdi`q]kdy$$IflF$&!    4 la1zz#$d$Ifa$gd2sd$IfVDWD^`sgdi`q]kd$$IflF$&!    4 la16:>qq#$d$&dIfPa$gd2sd$IfVDWD^`sgdi`q]kdy$$IflF$&!    4 la1>?@ABzz#$d$Ifa$gd2sd$IfVDWD^`sgdi`q]kd$$IflF$&!    4 la1BCgowqq#$d$&dIfPa$gd2sd$IfVDWD^`sgdi`q]kdy$$IflF$&!    4 la1wxyz{zz#$d$Ifa$gd2sd$IfVDWD^`sgdi`q]kd$$IflF$&!    4 la1{|zz#$d$Ifa$gd2sd$IfVDWD^`sgdi`q]kdy$$IflF$&!    4 la1zz#$d$Ifa$gd2sd$IfVDWD^`sgdi`q]kd$$IflF$&!    4 la1!"%efghyz{ !&')*`Үh654h9ARCJaJ h654h9ARCJPJaJnHtHh654h9ARCJaJo(#h654h9ARCJPJaJnHo(tH#h654hFCJPJaJnHo(tHh654hi`qCJaJ#h654hi`qCJPJaJnHo(tH h654hi`qCJPJaJnHtH4qq#$d$&dIfPa$gd2sd$IfVDWD^`sgdi`q]kdy$$IflF$&!    4 la1 !"#$rr#$d$$Ifa$gd2sd$$IfVDWD^`sgdi`qd$gdi`q]kd$$IflF$&!    4 la1$%efguu#$d$$Ifa$gd2sd$$IfVDWD^`sgdi`qbkdy$$IflF$&!    4 la1g&gh{#$d$$Ifa$gd2 & Fd$$1$Ifgdi`q]kd$$IflF$&!    4 la1#$d$$Ifa$gd2 & Fd$$1$Ifgdi`q]kd}$$IflF$&!    4 la1xx#$d$$&dIfPa$gd2 & Fd$$1$Ifgdi`q]kd$$IflF$&!    4 la1#$d$$Ifa$gd2d$$If^gd2]kdq$$IflF$&!    4 la1}}#$d$$&dIfPa$gd2 d$$Ifgd2]kd$$IflF$&!    4 la1#$d$$Ifa$gd2 d$$Ifgd2]kde$$IflF$&!    4 la1!')#$d$$Ifa$gdjW d$$IfgdjW]kd$$IflF$&!    4 la1)*`fjnn$sd$$IfVDWD^`sa$gdi`qsd$$IfVDWD^`sgdi`q]kdY$$IflF$&!    4 la1`ek"()³whS=hS=+h654hD>*CJOJPJQJaJnHtH(h654hDCJOJPJQJaJnHtHh654hDCJOJQJaJh654hDCJaJh654hD5CJ\aJh654h[5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654h[5CJ\aJo(h654hi`q5CJ\aJo(h654h9ARCJaJ h654h9ARCJPJaJnHtH#h654h9ARCJPJaJnHo(tHjkzzzz#$d$$Ifa$gd2sd$$IfVDWD^`sgdi`q]kd$$IflF$&!    4 la1qq#$d$$&dIfPa$gd2sd$$IfVDWD^`sgdi`q]kdS$$IflF$&!    4 la1)kWW%$!d$$Ifa$gd2{d$$IfWD^{`gd2d$gdDd^`gd}ad$gdi`q]kd$$IflF$&!    4 la1)*+6Aww%$!d$$Ifa$gd2{d$$IfWD^{`gd2]kdG$$IflF$&!    4 la1)+AUW BCQS÷ååoah654hh5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654h[5CJ\aJo(#h654h{,CJPJaJnHo(tH#h654hDCJPJaJnHo(tHh654hDCJaJo( h654hDCJPJaJnHtH h654hDCJOJPJ QJaJh654hD>*CJOJQJaJh654hDCJaJ#ABCKS||$d$$Ifa$gd2{d$$IfWD^{`gd2]kd$$IflF$&!    4 la1STUVWvv'$ d$$Ifa$gd2{d$$IfWD^{`gd2]kd;$$IflF$&!    4 la1WXvv'$ d$$Ifa$gd2{d$$IfWD^{`gd2]kd$$IflF$&!    4 la1ssssss$d$$&dIfPa$gd2Pd$$IfWD^`Pgd2]kd5$$IflF$&!    4 la1 x~nbSSS$d$^a$gd d^gdhd^`gd}ad$gdD$d$^a$gdD d$^gdD]kd$$IflF$&!    4 la1 (69@DOY}%&/<vwxy|ͻ}h)h654heu{5CJPJ\aJnHo(tHh654heu{5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654hh5CJ\aJo(h654hhCJaJo(#h654hCJPJaJnHo(tH h654hCJPJaJnHtHh654hCJaJo(h654hCJaJh654hhCJaJ"xyg]kd) $$IflFF!    4 la1$d$Ifa$gdjW d$IfgdjWdgd Adgdeu{$d^a$gdh 018AFGNWXY\ᷥᥔᅥrᥔᅥ$h654h]CJOJQJaJnHtHh654h]CJOJQJaJ h654h]CJPJaJnHtH#h654h]CJPJaJnHo(tHh654h]CJaJo(#h654h]>*CJPJaJnHtHh654h]>*CJaJh654h]CJaJ&h654h A5CJPJ\aJnHtH&#$d$Ifa$gdjW d$IfgdjW]kd $$IflFF!    4 la1#$d$Ifa$gdjW d$IfgdjW]kd!$$IflFF!    4 la119Auu#$d$&dIfPa$gdjWd$If^`gdjW]kdm!$$IflFF!    4 la1ABCDE#$d$Ifa$gdjW d$IfgdjW]kd!$$IflFF!    4 la1EFGOWxx$d$&dIfPa$gdjW%!d$IfgdjW]kdQ"$$IflFF!    4 la1WXYZ[ $$Ifa$gdjW%!$IfgdjW]kd"$$IflFF!    4 la1[\}} $$Ifa$gdjW%!$IfWD^`gdjW]kd5#$$IflFF!    4 la1uu#$d$&dIfPa$gdjWd$If^`gdjW]kd#$$IflFF!    4 la1 $$Ifa$gdjW%!$IfgdjW]kd$$$IflFF!    4 la1~~$$&dIfPa$gdjW%!$IfgdjW]kd$$$IflFF!    4 la1 $$Ifa$gdjW%!$IfgdjW]kd$$$IflFF!    4 la1#+~~$$&dIfPa$gdjW%!$IfgdjW]kdo%$$IflFF!    4 la1"+,-g  ,3yz| 58DJYiy9DNTȽ h654h ACJPJaJnHtHh654h ACJaJo(#h654h ACJPJaJnHo(tHh654h ACJaJh654h]CJaJ h654h]CJPJaJnHtH#h654h]CJPJaJnHo(tH(h654h]CJOJPJQJaJnHtH3+,- VWpYJ$d^a$gd A$ d7$8$H$^` a$gd A$ldWD^`la$gd A$ 7$8$H$^` a$gd Adgd A]kd%$$IflFF!    4 la1TVWXbcmno &(+018ABakͻͻ٩مم٩vdXdh654h ACJaJo(#h654h ACJPJaJnHo(tHh654h]CJOJQJaJ$h654h]CJOJQJaJnHtH h654h]CJPJaJnHtH#h654h]CJPJaJnHo(tH#h654h]>*CJPJaJnHtHh654h]>*CJaJh654h]CJaJh654h ACJaJ h654h ACJPJaJnHtH"WXcnopx]kdS&$$IflFF!    4 la1$d$Ifa$gdjW d$IfgdjW#$d$Ifa$gdjW d$IfgdjW]kd&$$IflFF!    4 la1#$d$Ifa$gdjW d$IfgdjW]kd+'$$IflFF!    4 la1zz#$d$Ifa$gdjW%!$IfWD^`gdjW]kd'$$IflFF!    4 la1 zz#$d$Ifa$gdjW%!$IfWD^`gdjW]kd ($$IflFF!    4 la1&)+}}#$d$&dIfPa$gdjW d$IfgdjW]kd{($$IflFF!    4 la1+,-./#$d$Ifa$gdjW d$IfgdjW]kd($$IflFF!    4 la1/019Axx$d$&dIfPa$gdjW%!d$IfgdjW]kd_)$$IflFF!    4 la1ABC}~/0{kTk$d7$8$H$^`a$gd Ad^`gd A$d7$8$H$a$gd&'$d^a$gd Adgd A]kd)$$IflFF!    4 la1B{|}~56 /01;<FGHnsz{䯣n h654h]CJPJaJnHtH#h654h]CJPJaJnHo(tH#h654h]>*CJPJaJnHtHh654h]>*CJaJh654h]CJaJh654h A>*CJaJ#h654h ACJPJaJnHo(tHh654h ACJaJo(h654h ACJaJ h654h ACJPJaJnHtH$01<GHIQY]kdC*$$IflFF!    4 la1$d$Ifa$gdjW d$IfgdjWYZ[\]#$d$Ifa$gdjW d$IfgdjW]kd*$$IflFF!    4 la1]^ntz#$d$Ifa$gdjW d$IfgdjW]kd+$$IflFF!    4 la1z{zz#$d$Ifa$gdjW%!$IfWD^`gdjW]kd+$$IflFF!    4 la1{  !8;EJQSnsz{ʿʿʿʿsssssssss h654h ACJPJaJnHtH#h654h ACJPJaJnHo(tH#h654h A>*CJPJaJnHtHh654h A>*CJaJh654h ACJaJh654h]CJaJ h654h]CJPJaJnHtH#h654h]CJPJaJnHo(tH$h654h]CJOJQJaJnHtH-zz#$d$Ifa$gdjW%!$IfWD^`gdjW]kd+$$IflFF!    4 la1}}#$d$&dIfPa$gdjW d$IfgdjW]kdk,$$IflFF!    4 la1 #$d$Ifa$gdjW d$IfgdjW]kd,$$IflFF!    4 la1 vv$d$&dIfPa$gdjW%!d$IfgdjW_kdO-$$Ifl\FF!    4 la1o_KPd$If^`PgdjWd^`gd A$d^`a$gd A$d7$8$H$^a$gd A d^gd A]kd-$$IflFF!    4 la1!"#+3~Pd$If^`PgdjW]kd7.$$IflF$&!    4 la1$d$Ifa$gdjW34567~~#$d$Ifa$gdjWPd$If^`PgdjW]kd.$$IflF$&!    4 la178EKR~~#$d$Ifa$gdjWPd$If^`PgdjW]kd/$$IflF$&!    4 la1RSntz~~#$d$Ifa$gdjWPd$If^`PgdjW]kd{/$$IflF$&!    4 la1z{~~#$d$Ifa$gdjWPd$If^`PgdjW]kd/$$IflF$&!    4 la1uu#$d$&dIfPa$gdjWPd$If^`PgdjW]kd_0$$IflF$&!    4 la1~~#$d$Ifa$gdjWPd$If^`PgdjW]kd0$$IflF$&!    4 la1uu$d$&dIfPa$gdjWPd$If^`PgdjW]kdC1$$IflF$&!    4 la156QRrj[H$d^`a$gd A$d^a$gd Adgd A$RdVDb^Ra$gd A$d7$8$H$^a$gd A $da$gd A]kd1$$IflF$&!    4 la1(246cw PR !(-/<AHIw$%*+hijkʸʸ֧֧֧֧֧֧ h654heu{h<^5CJ\aJ h654h ACJPJaJnHtH#h654h A>*CJPJaJnHtHh654h A>*CJaJ#h654h ACJPJaJnHo(tHh654h ACJaJh654h ACJaJo(9~]kd'2$$IflF$&!    4 la1$d$Ifa$gdjWPd$If^`PgdjW~~#$d$Ifa$gdjWPd$If^`PgdjW]kd2$$IflF$&!    4 la1~~#$d$Ifa$gdjWPd$If^`PgdjW]kd2$$IflF$&!    4 la1~~#$d$Ifa$gdjWPd$If^`PgdjW]kdk3$$IflF$&!    4 la1 "(uu#$d$&dIfPa$gdjWPd$If^`PgdjW]kd3$$IflF$&!    4 la1()*+,~~#$d$Ifa$gdjWPd$If^`PgdjW]kdO4$$IflF$&!    4 la1,-<BHuu$d$&dIfPa$gdjWPd$If^`PgdjW]kd4$$IflF$&!    4 la1HIJijl}ubRJdgd>d^`gd}a$0d^`0a$gdeu{dgd A$dVDJ^a$gd A$d7$8$H$^a$gd A]kd35$$IflF$&!    4 la1klpsƸ~mbmbN*CJPJaJnHtH$h654h]CJOJQJaJnHtH)h654h>5CJPJ\aJnHo(tHh654hv5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654h#5CJ\aJo()h654heu{5CJPJ\aJnHo(tH]kd5$$IflFF    4 la1$d$Ifa$gdjW %$IfgdjW$d$Ifa$gdjW %$IfgdjW]kd6$$IflFF    4 la1$d$Ifa$gdjW%!d$IfgdjW]kd6$$IflFF    4 la1}}#$d$&dIfPa$gdjW %d$IfgdjW]kd6$$IflFF    4 la1$d$Ifa$gdjW %d$IfgdjW]kdm7$$IflFF    4 la1#%&KPXYZ#*Y^bv{淬}}kkk#h654h>CJPJaJnHo(tH#h654h]>*CJPJaJnHtHh654h]>*CJaJ h654h>CJPJaJnHtHh654h>CJaJh654h>CJaJo( h654h]CJPJaJnHtH#h654h]CJPJaJnHo(tHh654h]CJaJh654h]CJOJQJaJ*$}}$d$&dIfPa$gdjW %d$IfgdjW]kd7$$IflFF    4 la1$%&zkk$d$Ifa$gdjW d$IfgdjW d^gd>$d^a$gd>]kdQ8$$IflFF    4 la1$d$Ifa$gdjW d$IfgdjW]kd8$$IflFF    4 la1#$d$Ifa$gdjW d$IfgdjW]kd/9$$IflFF    4 la1#$d$Ifa$gdjW d$IfgdjW]kd9$$IflFF    4 la1$*#$d$Ifa$gdjW d$IfgdjW]kd:$$IflFF    4 la1*+Y_c#$d$Ifa$gdjW d$IfgdjW]kdy:$$IflFF    4 la1cdv|yy#$d$&dIfPa$gdjWd$IfgdjW]kd:$$IflFF    4 la1#$d$Ifa$gdjW d$IfgdjW]kd];$$IflFF    4 la1}}$d$&dIfPa$gdjW %d$IfgdjW]kd;$$IflFF    4 la1 zSCd^`gd}a&9TPL HD@<+{^gd$ 7$8$H$^` a$gd>$d7$8$H$^a$gd>]kdA<$$IflFF    4 la18:Q_a ᪛xl`UD h654hyCJPJaJnHtHh654hyCJaJh654hyCJ\aJh654hvCJ\aJh654hv5CJ\aJ)h654h@5CJPJ\aJnHo(tHh654hv5CJ\aJo(4h654hvB*CJOJPJQJaJnHo(phtHh654h>CJaJ h654h>CJPJaJnHtH#h654h>CJPJaJnHo(tHh654h>CJaJo(  W]kd<$$IflF$a    4 la$d$Ifa$gd2 d$Ifgd20d^`0gdy$d^a$gd;0d^`0gdv #*[`gy| *08U[ctuz⧓тvh654hdCJaJo( h654hdCJPJaJnHtH&h654hyhBXCJPJaJnHtH#h654hyCJPJaJnHo(tHh654hy5CJaJh654hy>*CJaJ h654hyCJPJaJnHtHh654hyCJaJ#h654hy>*CJPJaJnHtH* $d$Ifa$gd2 d$Ifgd2]kd=$$IflF$a    4 la !"#$d$Ifa$gd2 d$Ifgd2]kd=$$IflF$a    4 la"#*+,#$d$Ifa$gd2 d$Ifgd2]kd=$$IflF$a    4 la,-[ag#$d$Ifa$gd2d$If^gd2]kdc>$$IflF$a    4 laghy}#$d$Ifa$gd2d$If^gd2]kd>$$IflF$a    4 lazz#$d$Ifa$gd2d$IfVDXWDj^`gdy]kdA?$$IflF$a    4 la#$d$Ifa$gd2 d$Ifgd2]kd?$$IflF$a    4 la#$d$Ifa$gd2 d$Ifgd2]kd%@$$IflF$a    4 la*18zz#$d$Ifa$gd2Hd$IfVDXWD8^`Hgdy]kd@$$IflF$a    4 la89U\c#$d$Ifa$gd2d$If^gd2]kd A$$IflF$a    4 lacdtvz#$d$Ifa$gd2d$If^gd2]kd{A$$IflF$a    4 laz{#$d$Ifa$gd2d$If^gd2]kdA$$IflF$a    4 la||#$d$Ifa$gd2Hd$IfWD8^`Hgdd]kd_B$$IflF$a    4 la()/LNUjkot#ղçòòòòuih654hyCJ\aJ&h654hyCJPJ\aJnHo(tH#h654hy5CJPJaJnHtHh654hy5CJaJh654hyCJaJ h654hyCJPJaJnHtH#h654hyCJPJaJnHo(tHh654hyCJaJo(h654hdCJaJo(#h654hdCJPJaJnHo(tH##$d$Ifa$gd2 d$Ifgd2]kdB$$IflF$a    4 la#$d$Ifa$gd2 d$Ifgd2]kdCC$$IflF$a    4 la)-/zz#$d$Ifa$gd2Hd$IfVDWWD8^`Hgdy]kdC$$IflF$a    4 la/0LOU#$d$Ifa$gd2d$If^gd2]kd'D$$IflF$a    4 laUVjlo#$d$Ifa$gd2d$If^gd2]kdD$$IflF$a    4 laopqrs#$d$Ifa$gd2 d$Ifgd2]kd E$$IflF$a    4 last#$d$Ifa$gd2 d$Ifgd2]kd}E$$IflF$a    4 lazzz#$d$Ifa$gd2d$IfVDXWDj^`gdy]kdE$$IflF$a    4 laqq#$d$&dIfPa$gd2d$IfVDXWDj^`gdy]kdaF$$IflF$a    4 la#$qr_}bb}b$ & F ;d1$^`;a$gds d^gdyd^`gdydgdy]kdF$$IflF$a    4 la #$ r9::_`awᰗnP:h654hzU5B*CJOJPJQJ\aJnHo(phtH+h654hm5B*CJOJQJ\aJph%h654hmB*CJOJQJaJph1h654hmB*CJOJPJQJaJnHphtH4h654h[B*CJOJPJQJaJnHo(phtHU&h654hyCJPJ\aJnHo(tHh654hyCJ\aJ#h654hyCJPJ\aJnHtHlished pricing policies for products and such pricing policies do not depend on whether or not the customers are State-owned Enterprises. Having due regard to the substance of the relationships, the directors of the Company are of the opinion that none of these transactions is a material related party transaction that requires separate disclosure.By Order of the BoardShandong Xinhua Pharmaceutical Company LimitedZhang DaimingChairman18 March 2011, Zibo, PRCAs at the date of this announcement, the board of directors comprises: Executive Directors:Mr. Zhang Daiming (Chairman)Mr. Ren FulongMr. Du DepingMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Sun MinggaoMr. Kwong Chi Kit, VictorNon-executive Directors: Mr. Xu Lie Mr. Zhao Bin PAGE PAGE 11_`aw 5Rao $7$8$H$If)$a$$^a$ $ ^ a$gdq"$0TPL HD@< ^ a$$ ^ a$#9TPL HD@<+{^ ̫ububI:%:)h654hmB*OJPJQJnHphtHh654hmB*OJQJph1h654hmB*CJOJPJQJaJnHphtH%h654hmB*CJOJQJaJph4h654hmB*CJOJPJQJaJnHo(phtH4h654hzUB*CJOJPJQJaJnHo(phtH@h654hm56B*CJOJPJQJ\]aJnHo(phtH+h654hm6B*CJOJQJ]aJph:h654hm5B*CJOJPJQJ\aJnHo(phtH   679F`aoxyҲҲҲҗۀiҗSKjh"tU+h654hmCJOJPJQJaJnHo(tH,h654hmB*OJPJQJnHo(phtH,h654h{6B*OJPJQJnHo(phtHh654hmKHaJh654hqKHPJnHo(tHh654hmKHPJnHo(tHh654h{6KHPJnHo(tHh654hmKHh654hmB*OJQJph)h654hmB*OJPJQJnHphtH]GkdG$$If0!64 aGkdEG$$If0!64 a )$$Ifa$ $7$8$H$If  !#$-./;<=>?@ABCD#$a$##&`#$!"$%+,-/0679:;<=>BCD̶+h654hmCJOJPJQJaJnHo(tHhm hso(h=~0J$mHnHuhs hs0J$jhs0J$Ujh"tUh"t/0P/ =!"#$n% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCBO> NotesdB*CJaJphO Body textc$>TPL HD@<Td1$7$8$H$^Ta$-B*CJOJQJ_HaJmH nHphsH tHHOH Subhead 1Td^T ;CJaJ~O~ Subhead 2B$'PL HD@<Q^`a$5B*\phDZ@D ~e,g$a$CJOJPJQJ aJnHtH<O< write $a$CJPJnHtHpOpChar Char Char Char!d1$CJKHPJaJmHnHtHu.". yblFhe,g"CJaJ6 @26 u#9r G$CJaJ)@A uxP@RP u w%!d1$CJKHOJPJ QJaJtH 0b0 le,g&G$CJaJPOrP Anrede' 1$KHOJPJQJaJtH VOV W[CQ W[CQ(d1$CJKHPJaJmHnHtHudOd Default)1$7$8$H$-B*CJOJQJ_HaJmH nHphsH tH O med1HH  Balloon Text+CJOJQJ^JaJ4O4 cke1,B*OJQJph0`@0 HTML 0W@W-6]Be@B  HTML @P h/$<@&a$5CJ OJPJQJ\^JaJ K@ y|T0([@( 5uP[N~{T1\J@"\ oRh2$d8<@&a$"5CJ KHOJPJQJ\^JaJ -2 [e,g43 ` @ 1$3$5$7$8$G$0CJKHOJ PJQJ ^J _HaJmH nHsH tH6%@B6 [ON0W@W4G$ OJQJ^J.?@R. ~_g5dVD4^d4/@b4 Rh68WD8^`8<2@r< Rh 27d8VDWD8^d`8<3@< Rh 38d8VDWD8^d`8<4@< Rh 49d8VDXWD8^d`8<5@< Rh 5:d8VD WD8^d`8,1@, RhS ; & F0:@0 RhS 2 < & F0;@0 RhS 3 = & F0<@0 RhS 4 > & F0=@0 RhS 5 ? & F4D@4 Rhc~@xVD^8E@8 Rhc~ 2AHxVD^H8F@"8 Rhc~ 3BxVDX^8G@28 Rhc~ 4CxVD ^8H@B8 Rhc~ 5D4xVD^400@R0 Rhyv&{S E & F46@b4 Rhyv&{S 2 F & F47@r4 Rhyv&{S 3 G & F48@4 Rhyv&{S 4 H & F 49@4 Rhyv&{S 5 I & F $$vU_ 1J00vU_ 2KVD^00vU_ 3LHVD^H00vU_ 4MVDX^00vU_ 5NVD ^00vU_ 6O4VD^400vU_ 7P VD^ 00vU_ 8Q| VDx^| 00vU_ 9R VD@^ $2$ TybleW[SROAR Ss Char Char1$CJKHPJ_HaJmH nHsH tH*j12* Vybl;NU5\2OBa2 Us Char Char5\(^@r( nf(Qz)W,@@, ~{TXdVD4^d,L@, egYdVD ^dX$@X 6eON0W@W(Zd&+D/G$VDx^d OJQJ^J$ $"}_ 1[0 0"}_ 2\VD^0 0"}_ 3]VD^00"}_ 4^XVDX^X00"}_ 5_ VD ^ 00"}_ 6`VD^00"}_ 7aVD^00"}_ 8bxVDx^x00"}_ 9c@VD@^@6!6 "}_hd5OJQJ\^J8"8 leCJOJPJ QJ^JaJ4#4 VhvU_f8VDWD8`8(+r( >\le,ggG$>T@> e,gWWhxUDVD]^8Y8 ech~gVi-D M I@ Oo`hoj8$d%d&d'd-DM NOPQVDWD ^8` OJQJ^J0,0 _evU_kVD^<.< _evU_hlxOJPJQJ^J(B@( ckee,gmx4M@4 ckeL)ۏnWDd`8C@8 ckee,g)ۏoxVD^8N@8 ckeL)ۏ 2pWD`0@0 cke)ۏqWD`2P@"2 ckee,g 2 rdx4Q@24 ckee,g 3sxCJaJBR@BB ckee,g)ۏ 2tdxVD^DS@RD ckee,g)ۏ 3uxVD^CJaJ*O@* lʑhv$a$6Oq6 short_text1CJaJ8O8 medium_text1CJaJ4O4 long_text1CJaJvOv T Report Text-z$d1$5$7$8$9DH$^a$KHPJ aJmH sH tH JOJ T body text{xx1$CJKHaJtH VOV TRQk=|d1$WD`CJKHOJPJ QJaJtH O z hps`` sQ?Z_dkpqHMRglm"9=>(,7;<=BG^st 12FGYdo~ &5DSbc'6CRSeftulmvwHIxz  x y !!""##($)$$$%%%%&&8)9)M)N),,],^, . ...//00-1.144>5?5558797999:::$<%<<<==>>2?3?>B?BLBMB`DaDGGGG?H@HIIKKoLpL[M\MMMNNQQ%R&RRRTTJVKVXXgXhXYY[[[[\\]]O_P___``aaaaabbbbwcxcccddddee!e&e/e5e=e>e]eeeeeeeeeffffEfKfQfRfbfdfhfif~ffffffffffff.g0g4g5gEgFgGgHglgpgrgsggggggggggggghhhhChGhKhLhqhrhiiiijjkkkk[m\mmmmmnnnn7o8oSoToooooqq-r.rErFrsssttjtktptutzt{t|ttttttttttuu/uAuSueuwuxuuuuuuuuvv*vwNwOwjwywwwwwwwwwww+x-x/x=xKxLxixwxxxxxxyyy*y+y?yOy^yny~yyyyyyyyyyzz,z-zfzuzzzzzzzzzzz{({7{F{U{V{o{{{{{{{|||,|-|G|U|W|e|||}|||||||||||||||||}}#}4}E}T}c}d}}}}}}}~)~,~<~I~J~~~~~~~~~~~%&DEFLWbcdep{|}~ƁǁӁ߁ "()*+,-.;<CIJKLMNOfgpyz{|}~ԂՂ߂&'09:;<=>?^_eklmnopqƒÃăŃƃǃۃ݃34<CD^_eklmnopqrs{Ʉʄ˄̄ #./019ABCDEFGHIJKL`aiqrstuvw56?@HIʆˆІ҆ӆ%&'()*+ijst{|}~239?@ABCDEFGNVWXΈψЈш҈ 89AIJtu}ĉʼn̉Ӊԉ &'PQWYZ[\]^_`akuvwxyz{ȊɊˊӊۊ܊>?AGHmnqst͋΋֋ދߋ%,-./01234>HIJKLMNbcdefی܌ތ  !)12UVWXYuv|~Íčōƍ ./7?@IJT^_wxĎΎώ  !"#$%&>?@AB[\bijuv~ÏďŏƏЏڏۏ܏ !9:ϒВ!"6RSeғ45I}~23Hst|uvŘƘ#$8%opқӛ'CDXyzȜɜܜɝ R۞!"ЦѦCD~MNij67M @ABCD[\VW{|}~հְװ !"#$%&'/0123456GQYahjtu±̱Աܱ &,-56789:;<=>QRSTUV]^_`abcdef{|}~ֲײزٲڲ۲ 9:;<QRS`awij̳Գܳݳ޳߳%'12FLT[cmopqrstuvwxδִݴ !"#$%:;<=>?HIJKLMNOPQ_`abcdmnopqrstuvɵʵ˵bcwxyθϸոָ׸߸ (08BCDEFGHIJhijkltuvwxyz{|¹ʹѹع  9:;<=GHIJ^_`uvƺκֺ޺)*+,-./01OPQRS[\]^_`abcwxyz{ǻȻɻʻ˻̻ͻλϻ !"#$,-.,-GHlmɿʿ׿ "*2:;<=>?@ABipw{ ?CFLNTUIJno 0LMSTU]emu}~&'5>FKOXYlu}'=YZ`abjrz PV[]agh<=!"#+3;CKLMNOPQRSlnuwy '(;CKS[def $/019ABCDEFJT^_fnvwpq29@Aw}  !:;<GRST_jklt|}~ !"#$%&-456"#=> 06:;u{ (.45mt{|06:;ahjklmnopw{|}~@AIJRS"#$%&uvw~34]^123>IJKS[\]^_`|$+,emuvwxyz{*2:;flrs ;AGHvz~fg 26:;`hpqrstu*+,1678@HIJKLMZ`fg!"#.9:;CKLMNOP_gop89:EPQRZbcdefgw %-./|}qrs~ceijklmn $&)*hoqrstuv 1234owxxy./0Fu!0>OPu 000000000000000000000 0 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 v0 0 0 0 0 00000000 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 00 00 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 00 00 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 000 0 00 0 0 0 0 0 0 0 00000 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 00 00 0 00 0 0 0 v 0 0 0  0 0 0  0 0 0  0 0 0  0 0 0  #0 #0 0  0 0 0  0 0 0 0 0 0 0  0 0 0  0 0 0  0 0 0 0 0 0 0  0 0 0  0 0 0 00000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0 0000000000000 %0 %0 %0 0 0 %0 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 00000 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0  0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0  0 %0 %0%0 0  0 %0 %0 0  00 %0 %0%0 0 0 0 %0 %0 0  0 %0 %0%0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 %0 0 0 0 %0 %0 0  0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 000 %0 % %0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 0 000 0 0 000 0 0 000 0 0 000 0 0 000 0 0 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000000  0   0   0   0   0   0   0   0   0   0 00000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 000 00 0000000000000000 0 0  0 0  0 0  0 0  0 0  0 0  0 0 00 00 000 00 0 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 000 00 0 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 0000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0|000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0  0 0 0 0 0 0  0 0 0 0 0 0  0 0 0 0 0 0  0 0 0 0 0 0 0 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 %0 0  %0 %0 0  %0 %0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000000000 %0 %0 0 0 %0 %0 0 0 0 0 0 0 '0 '0 0 0 '0 '0 0  0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 %0 %0 0 0 %0 %0 0 0 0 0 0 0 '0 '0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 %0 0 0 0 0000000000 %0 %0 0  %0 %0 0  0 0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0    0  #0#0 #0#0 0  #0 #0 0 000 %0 %0 0  %0 %0 0  0 0 0  '0 '0 0  '0 '0 0  000 000 0 000000000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 % 0 0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 0000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 % #0 #0 0 % #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 00000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 % #0 #0 0 % #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 0 0 0 0000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 0 0 0 00000%0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 #0 #0 0 %0 0 0 0 %0 0 0 0 0000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 0000000000 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0#0 0  #0 #0 0 000 00 00 000000000)0)0000000 0)000 0 )0)0)0 0 0 0@0I00@0I00@0I00@0I00@#0@#0@0@#0@#0@0I00| 0000|X qrsuv"CD "'/08CNYZlu~ AJRZ[\]^_`a :CLUV    ; @ D E \ m ~ & 5 < J K    . / 4 K O f j 8 I Z _ p q  (-29>?Z_dkpqHMRglm"9=>(,7;<=BG^st 12FGYdo~ &5DSbc'6CRSeftumvwxz  x y !!""##($)$$$%%%%&&8)9)M)N)aaabbbbwcxcccddddee!e&e/e5e=e>e]eeeeeeeeeffffEfKfQfRfbfdfhfif~ffffffffffff.g0g4g5gEgFgGgHggggggggggggghhhhChGhKhLhqhrhiiiijjkkkk[m\mmmmmnnnn7o8oSoToooooqq-r.rErFrsssttjtktptutzt{t|ttttttttttuu/uAuSueuwuxuuuuuuuuvv*vwNwOwjwywwwwwwwwwww+x-x/x=xKxLxixwxxxxxxyyy*y+y?yOy^yny~yyyyyyyyyyzz,z-zfzuzzzzzzzzzzz{({7{F{U{V{o{{{{{{{|||,|-|G|U|W|e|||}|||||||||||||||||}}#}4}E}T}c}d}}}}}}}~)~,~<~I~J~~~~~~~~~~~%&DEFLWbcdep{|}~ƁǁӁ߁ "()*+,-.;<CIJKLMNOfgpyz{|}~ԂՂ߂&'09:;<=>?^_eklmnopqƒÃăŃƃǃۃ݃34<CD^_eklmnopqrs{Ʉʄ˄̄ #./019ABCDEFGHIJKL`aiqrstuvw56?@HIʆˆІ҆ӆ%&'()*+ijst{|}~239?@ABCDEFGNVWXш҈IJӉԉ&'YZ^_uvz{ۊ܊GHstދߋ,-12HIMNef12XY~ōƍ ?@^_Ύώ !%&ABijÏďŏƏЏڏۏ܏ !9:ϒВ!"6RSeғ45I}~23Hst|uvŘƘ#$8%opқӛ'CDXyzȜɜܜɝ R۞!"ЦѦCD~MNij@ACD&'56tu56=>]^ef ܳݳ12opwx$%HIPQmnuvɵʵոָBCIJtu{| GH)*01[\bcǻȻλϻ"#$,-:;ABTUST}~&'XY`agh!"KLRS'(de/0ABEF^_vw29@Aw}  !:;<GRST_jklt|}~ !"#$%&-456"#=> 06:;u{ (.45mt{|06:;ahjklmnopw{|}~@AIJRS"#$%&uvw~34]^1:;pqtu67HILMfg!}qrs~ceijklmn $&)*hoqrstuv 1234owxxy.0000000000000000000000 00 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 t0 0 0 0 0 000000000 00 00 00 0 @0 K0L0XM4 @0 @0 K0O0VP\4 @0 0 0 0 0 0 0 0 0 0 0 0( 00000 00 00 0000 0 0 0 0 0 0 0 0 0 0 000 @0 @0 @0@0@0 @0 @0 @0@0@0 0 0 0 000000000000@0@0 @0@0@0 @0 @0 @0 @0 @0 @0 @0@0@0@0@0@0@0 000000 00 000 00000000000000000000000000000000000000000 000 0 00 000000000000 00 00 0 0 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00 00 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00 0 0 0 0 000000000000000000000000000000000000000000000000000000000000 00 00 000 0 0 0K00)@0 @0 @0K00)@0 @0 @0K00)@0 @0 @0K00)@0 @0 @0K00 )@0 @0 @0K0 0 )@#0@#0@0 K0 0)@0 @0 @0K00)@0 @0 @0@0 @0@0 @0@0 @0@0 @0@0 @0@0 @0@0 @0@0 @0@0 @0 @0 @0@0 @0 @0 @000000000000000000000000000000000000000000000000 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 000000 0000000000000 %0 %0 %0 00 %0 %0 %0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 0@0 @0 @0 @0 @00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 0@0 @0 I03TI00 @00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 #0 #0 000000 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0%0 0 0 0 %0 %0 0 0 00 %0 %0%0 0 0 0 %0 %0 0 0 0 %0 %0%0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0K03\@ 0 K03\x 0 K03\ 0 K03\ 0 K03\ 0 K03\X 0 K03\ 0 K03\ȗ 0 K03\ 0 K03\8 0 K03\p 0 K03\ 0 K03\ 0 K03\ 0 K03\P 0 K03\ 0 K03\ 0 K03\ 0 K03\0 0 K03\h 0 K03\ 0 K03\ؚ 0 K03\ 0 K03\H 0 K03\ 0 K04\ 0 K04\ 0 K04\( 0 K04\` 0 K04\  0 K0 4\ М 0 K0 4\ 0 K04\@ 0 K04\x 0 K04\ 0 K04\ 0 K04\ 0 K04\X 0 K04\ 0 K04\Ȟ 0 K04\ 0 K0 4\!8 0 K0"4\#p 0 K0$4\% 0 K0&4\' 0 K0(4\) 0 K0*4\+P 0 K0,4\- 0 K0.4\/ 0 K004\1 0 K024\30 0 K00@0 K00@0 K00@0 K00@0 K00 @0 K0 0 @0 K0 0@0 K00@0 K00@0 K00@0 K00@0 K00@0 K00@0 K00@0 K0N4Ot2I0N4 I0N4  I00@0 000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000+ 00+ 00000000000000K05l0 K05l0 K05l0 K05,l0 K05dl0 K05l0 K05l0 K04:,0 K04:d0 K04:0 K04:ԫ0 K04: 0 K04:D0 K04:|0 K04:0 K04:쬜0 K04:$0 K04:\0 K04:0 K04:̭0 K04:0 K04:<0 K04:t0 K04:0 K04:䮜0 K04:0 K04:T0 K04:0 K04:į0 K04:0 K04:40 K04:l0 K04:0 K05:ܰ0 K05:0 K05:L0 K05:0 K0 5: 0 K0 5: 0 K05:,0 K05:d0 K05:0 K05:Բ0 K05: 0 K05:D0 K05:|0 K05:0 K05>쳜K05=K05<K05:0 K05_< 0 K05_t 0 K05_ 0 K05_ 0 K05_  0 K0!5_"T 0 K0#5_$ 0 K0%5_&Ļ 0 K0'5_( 0 K0)5_*4 0 K0+5_,l 0 K0-5_. 0 K0/5_0ܼ 0 K015_2 0 K035_4L 0 K055_6 0 K075_8 0 K095_: 0 K0;5_<, 0 K0=5_>d 0 K0?5_@ 0 K0A5_BԾ 0 K0C5_D 0 K0E5_FD 0 K0G5_H| 0 K0I5_J 0 K0K5_L 0 K0M5cN$ K0M5b K0M5a K0M5_ 0 K0W6XDl0 K0Y6Z|l0 K0[6\l0 K0]6^l0 K0_6`$l0 K0a6b\l0 K0c6dl0 K0e6fl0 K0g6hl0 K0i6joĖɖF~ޗ INeИ*MgÙ+0lqɚ9chԛ).ER*ޡ=3vƻjAWY߽%-cek|Ⱦʾо !ALNThuw}GIOX^p "(9_ag{ '46@Jkq KNS')QUY 249^jlq{7r?BG Gz$Gf '9;F_w-I[_o>uy$RVfj/3s>Bw{$g)j)ASWxAEW[+W+/A0Y]z 37Rz(,H$*c ",g8cz/Uos_D    !"#$%'()*+-./12789:;<>?@ABCDEFGHIJKLNOPQRSTVWXYZ[\]^_`acdefghijlmnoprstuvwxyz|}~     !#$%&'()*+,-./01235689:;<=>?@ABCDEFHIJKLMNPQRSTUVWXYZ[\]^_`abcdfghijklnopqrtuvwxy{|}~    !"#$%&'()*,-./012356789;<=>?@ABCDEGIJKLMNOPQRSTUWXYZ[\]^_`dghC !(!!l,b$l?xK-}*1@(  f  c 6A!SHANDONB S  ?s`8t OLE_LINK4 OLE_LINK7 OLE_LINK6 OLE_LINK8 OLE_LINK9 OLE_LINK13 OLE_LINK14 OLE_LINK33 OLE_LINK100 OLE_LINK101 OLE_LINK12 OLE_LINK15_Hlk252804176 OLE_LINK2 OLE_LINK30 OLE_LINK28 OLE_LINK29_Hlk252956248LLX9+++   VV\?777^ [| [\ [[L[|)[)[)[4[t[[[4@ [t@ [@ [@ [4A [tA [A [A [4B [H[H [I![DI"[I#[I$[J%[DJ&[J'[J([K)[DK*[K+[K,[L-[DL.[/[0[41[t2[3[4[45[t6[7[8[49[t:[;[<[4=[t>[?[@[T0 A[0 B[T1 C[1 D[T2 E[2 F[2 G[T3 H[3 I[4 J[T4 K[4 L[5 M[5 N[6 O[6 P[7 Q[7 R[<S[T[DU[V[DW[X[DY[Z[D[[\[D][^[D_[`[Da[b[c[d[De[f[g[D%="""-222F4F4M4\4e4p4>>l>l>B!B*B*B3B~B~BKKKOMOMRRRaVaVhVwVVVeeJgJgggnnrep#$_wwT_3>#.:E66    ! "'#$%&()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]J"""-222L4[4d4o4t4t4>&>q>q> B%B2B;B;BBBKKKWMWMRRRgVvVVVVVeeNgNgggnnsoz"-#.e^i'=H-8DO::   ! "$%&'#()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]9?*urn:schemas-microsoft-com:office:smarttagsStateB]*urn:schemas-microsoft-com:office:smarttagscountry-region=U*urn:schemas-microsoft-com:office:smarttags PlaceType=V*urn:schemas-microsoft-com:office:smarttags PlaceName8Y*urn:schemas-microsoft-com:office:smarttagsCity9^*urn:schemas-microsoft-com:office:smarttagsplace<\*urn:schemas-microsoft-com:office:smarttagschmetcnv;**urn:schemas-microsoft-com:office:smarttagschsdate L701122000000020092010 30731283031aDayFalseHasSpacein IsLunarDate IsROCDateMonthNegative NumberType SourceValueTCSCTrueUnitNameYear^]\ \  ^Y^^VU^VVVVUVU^]VU^VU^]^VU^?^VU^VVVVU^Y^Y^Y^Y^^Y*   *   *   *   * * ^]*   *   ^^]*   *   *   *   *   *   *   *   \ *   *   *   *   *   *   *   *   *   *   *   *   ^Y^Y^Y^YvJT""""]&e&**D-J-j-p-//0011:2K22222#3+355 6.6E6S6]6g6n6z6{66Z7d7J8P8o8}8=9H9::::;;;+;<<<<>>B B'D1DDEKKQQRRTT|UUVVVV[[#\/\4\=\\\]]7`?`eefele9f@fjjk%kqqJqSqxqqssݐߑtzВ֒"(FLMSsy$*HNѡڡĤ;GT^gqyOU{%()/467=GN} !Gut}%!$!!!""$$.,/Z0b09:::<<??8A@ABCKC__mcuc܏۞im||X` s3333333333333333333333333333333klA`V ;  K J K j 8 qHm">( &cfaae>eeeffEffff.gHglgsggghhChLhMhrhiiooktttw+xxx/zfz{{}~O~~~F ;<fg?_̄6Iˆӆ+jJu'Q܊?Hn܌Yvƍ?B܏В"eғ5I~3Ht|$8%pzɜܜM D\~۲<v˵cwy.Bi?UPhe2Aw:<6;u5m|/0;aASw13IK[`+eu{:fr;Gv~2;`,!#9;KPo:PRbg-sc*h4o!0NPu  |0b?}8.>~ڟL=R<4-I:H VGZ>Y?^@xn@H3ACBa,C6D7DinD4EJE`)F;F)G>HH->HxWHaIIzK-L9LfmLwN*OR9ARqR,;S`OSmSRT2UzU*WsWj}XY1Y$@YCZ/$[z[ 3\oY\+c\B^7_n=_\`}aJb_b4Ecd1YdR'e/eHe]4fAfgzg#h=NhMi4iati_|i0j4j2lmimz n%ynao qi`qDrqrp-s{Xshs"tKStuv=!wox%yy.3y/Azeu{8|?|-}jy}E~hl~C (iUi[d~|PvbHz)Nm}?.tRvz o9qgC_hk  CU:ml!uG Pu3Jhdh;[}aR` a {x$X&. F7az~U9 q'f*cdR|!k|.Y-y,,0g:*SM|.PoqM"h0bs' A`dFls[?J08J6jW #BxeH8$2u}h LiO c#&~XkD!I MkV,Bcuf[ (%n9~]'alT"T0V+ OR"'R*rd&'"C(pL/>2UW=]=^ #(?u18Iu) ]$:'1`,-D%0*I,CqkYZg (oE &^,u7r:O pLdV ;z)sB\`V axyh|{6Tkm8KUkv>vhW}kK:b{""/08CNYZlu~ AJRZ[  :CLUV  ; D E \ m ~  & 5 < J K    . / 4 O j 8 I Z _ p q (-29>?Z_dkpqHMRglm"=>,;<=BG^st 12FGYdo~ &5DSbc'6CRS>lHaaade!e/e=e>eeeeeeeeeffffEfKfQfRfbfdfhfif~ffffffffffff.g0g4g5gEgFgGgHglgpgrgsggggggggggggghhhhChGhKhLhktptutzt{t|ttttttttttuu/uAuSueuwuxuuuuuuuuvv*vwNwOwjwywwwwwwwwwww+x-x/x=xKxLxixwxxxxxxyyy*y+y?yOy^yny~yyyyyyyyyyzz,z-zfzuzzzzzzzzzzz{({7{F{U{V{o{{{{{{{|||,|-|G|U|W|e|||}|||||||||||||||||}}#}4}E}T}c}d}}}}}}}~)~,~<~I~J~~~~~~~DEFLWbcdep{|}~ƁǁӁ߁ "()*+,-.;<CIJKLMNOfgpyz{|}~ԂՂ߂&'09:;<=>?^_eklmnopqƒÃăŃƃǃۃ݃34<CD^_eklmnopqrs{Ʉʄ #./019ABCDEFGHIJKL`aiqrstuvw56?HIʆˆІ҆ӆ%&'()*+ijs{|}~239?@ABCDEFGNVWXΈψЈш҈ 89AIJtu}ĉʼn̉Ӊԉ &'PQWYZ[\]^_`akuvwxyz{Ɋˊӊۊ܊>?AGHmnqst͋΋֋ދߋ%,-./01234>HIJKLMNbcdefی܌ތ  !)12UVWXYuv|~Íčōƍ ./7?@IJT^_wxĎΎώ  !"#$%&>?@AB[\bijuv~ÏďŏƏЏڏۏϒВ!"6RSeғ45I}~23Hst|#$8%opқӛ'CDXyzȜɜܜ۞ Mj67M @ABCD\W{|}հ !"#$%&'/0123456GQYahjtu±̱Աܱ &,-56789:;<=>QRSTUV]^_`abcdef{|}~ֲײزٲڲ۲ 9:;Q`wij̳Գܳݳ޳߳%'12FLT[cmopqrstuvwxδִݴ !"#$%:;<=>?HIJKLMNOPQ_`abcdmnopqrstuvɵʵcwxyθոָ׸߸ (08BCDEFGHIJhijkltuvwxyz{|¹ʹѹع  9:;<=GH^_`uƺκֺ޺)*+,-./01OPQRS[\]^_`abcwxyz{ǻȻɻʻ˻̻ͻλϻ !"#$,--mɿ׿ "*2:;<=>?@ABipw{ ?CFLNTUo 0LSTU]emu}~&'5>FKOXYlu}'=Y`abjrz PV[]agh!"#+3;CKLMNOPQRSlnuwy '(;CKS[de $/019ABCDEFJT^_fnvwq29@Aw} :;<GRST_jklt|}~ !"#$%&-45R"#> 06:;u{ (.45mt{|06:;ahjklmnopw{|}~@IRS"#$%u~^123>IJKS[\]^_`|$+,emuvwxyz{*2:;flrs ;AGHvz~ 26:;`hpqrstu*+,1678@HIJKLMZ`fg!"#.9:;CKLMNOP_gop89:EPQRZbcdefgw %-.|}qrs~ceijklmn $&)*hoqrstuv 1234owPYTIda2a2a2 y0a2)+59=y0C$y0y0}9/Ha2_3]=K'@EfEf|QEfEfdvv|}p@p p@pp4@pp@p@Unknown Lenovo UserG0536A0509UserGz Times New Roman5Symbol3& z ArialC .PMingLiUe0}fԚU.{ @CalibriCentury Gothic;[SOSimSung HelveticaNeueLTStd-LtN[_GB23123Times] Times-BoldTimes New Roman?5 .MingLiU0}fԚ[ (DFPFangSongW4-B5PMingLiU;ўSOSimHei?5 z Courier New;& Helvetica5& zaTahoma;Wingdings]SimSunLucida Sans Unicode FCK%%!xxdff2qHX?8|2 2006 ANNUAL RESULTS ANNOUNCEMENTWonderful Sky_o(u7bL           Oh+'0(8 LX x  $2006 ANNUAL RESULTS ANNOUNCEMENTWonderful Sky$generated by an Adobe applicationNormal ΢û331Microsoft Office Word@v0@ @Tb@\)A%՜.+,0 `h Wonderful Skyxf   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry F` -AData G1Table$^WordDocumentSummaryInformation(DocumentSummaryInformation8CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q